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NOVEL ROLE OF ACETYLCHOLINE IN VASCULAR CONTROL IN HUMANS 
The vascular endothelium is remarkably sensitive to the molecule acetylcholine (ACh), 
which binds to muscarinic receptors to initiate endothelium-dependent vasodilation. Although 
vasodilatory responsiveness to ACh is considered the gold standard index of endothelial 
function, an obligatory role for ACh in peripheral blood flow control has been challenging to 
elucidate. Thus, muscarinic ACh receptors on endothelial cells are widely considered to be 
evolutionary remnants with no real physiological function in humans. Administration of 
exogenous ACh amplifies endothelial sensitivity to other vasodilatory stimuli and blunts 
sympathetic vasoconstrictor signaling; therefore, we sought to determine whether endogenous 
ACh contributes to these processes in vivo. Accordingly, the overall goal of this dissertation 
research was to evaluate the role of ACh in modulating sympathetic α-adrenergic 
vasoconstriction and eliciting vasodilation in healthy, young adults.  
The primary findings are that 1) ACh interacts with the endothelium-dependent 
vasodilator adenosine triphosphate (ATP) to augment vasodilation and limit α1-adrenergic 
vasoconstriction in the skeletal muscle resistance vasculature, 2) endogenous ACh blunts 
sympathetic vasoconstriction within active skeletal muscle and is an obligatory mechanism of 
functional sympatholysis during exercise at high intensities, and 3) ACh mediates flow-induced 
vasodilation of conduit arteries in response to sustained and transient increases in shear rate 
induced by handgrip exercise and reactive hyperemia, respectively. Collectively, these studies 
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CHAPTER 1 – RATIONALE & EXPERIMENTAL AIMS 
INTRODUCTION 
The vascular endothelium is a single layer of cells that lines entire cardiovascular system 
and fundamentally contributes to all aspects of cardiovascular function. Endothelial cells 
constantly monitor chemical and mechanical cues and communicate with underlying vascular 
smooth muscle cells to regulate vascular tone; thus, the endothelium plays a critical role in 
regulating blood flow and tissue oxygen delivery. Because of its essential role, a decline in 
endothelial function has long been recognized as an independent risk factor for cardiovascular 
disease. Accumulating evidence suggests that the endothelium is a key site for integration of 
information from the bloodstream, sympathetic nervous system, and surrounding tissues; yet, 
how the endothelium processes simultaneous stimuli and transduces signals to control arterial 
diameter is not entirely clear.  
Role of acetylcholine in regulating vascular tone  
The endothelium is so profoundly sensitive to the molecule acetylcholine (ACh) that 
administration of ACh is considered the gold standard assessment of endothelial health. 
However, despite the close association between endothelial dysfunction and cardiovascular 
disease risk, numerous attempts to elucidate a physiological role of ACh in blood flow regulation 
in humans have been unsuccessful (Armstrong & Laughlin, 1986; Buckwalter et al., 1997; 
Shoemaker et al., 1997; Brock et al., 1998). Because ACh is classically regarded as a 
neurotransmitter, researchers historically investigated the possibility that ACh was released by 
sympathetic vasodilator nerves or “spilled over” from motor nerve terminals (Corcondilas et al., 
1964; Donald et al., 1970; Williams et al., 1985; Joyner et al., 1992; Welsh & Segal, 1997).   
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More recent evidence from isolated vessels demonstrates that vascular endothelial cells 
synthesize and secrete ACh in response to shear stress (Wilson et al., 2016), which then binds to 
muscarinic receptors to elicit vasodilation in an autocrine manner. Evidence of this 
non-canonical source of ACh released directly to the circulation raises the possibility that local 
cholinergic mechanisms may regulate vascular tone in humans. 
Muscle blood flow regulation and functional sympatholysis 
During whole-body exercise, elevated sympathetic nervous system-mediated 
vasoconstriction limits blood flow to inactive tissues, which facilitates redistribution of blood to 
metabolically-active skeletal muscle without compromising arterial blood pressure.  Although 
sympathetic nerve activity is also increased to skeletal muscle circulation, post-junctional 
α-adrenergic vasoconstriction is substantially blunted in the vasculature of contracting muscle 
(Remensnyder et al., 1962). This ability of working skeletal muscle to modulate sympathetic 
vasoconstriction, termed ‘functional sympatholysis’, is essential to ensure adequate blood flow 
and oxygen delivery to active muscle in the face of elevated sympathetic outflow. Advancing age 
and many disease states are characterized by a combination of elevated sympathetic nerve 
activity and an impaired ability of contracting skeletal muscle to limit sympathetic 
vasoconstriction (Dinenno et al., 2002; Saltin & Mortensen, 2012). The resulting malperfusion of 
working skeletal muscle limits delivery of oxygen and substrates to metabolically-active tissue, 
which accelerates fatigue development and diminishes exercise tolerance (Tyni-Lenné et al., 
1996; Mortensen et al., 2012). Thus, elucidating the signaling mechanisms that underlie 
functional sympatholysis in humans is an important biomedical goal with implications for 
understanding and treating exercise intolerance in aging and clinical populations.  
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Mechanisms of functional sympatholysis  
The mechanisms that modulate α-adrenergic signaling within active skeletal muscle 
remain poorly understood (Saltin & Mortensen, 2012). However, mounting evidence suggests 
that the vascular endothelium is a critical site for integration of local vasodilatory and 
sympathetic vasoconstrictor signaling (Behringer & Segal, 2012a; Kerr et al., 2012; Hearon et 
al., 2016), and evidence from experimental animals suggests that hyperpolarization originating in 
 
 
Figure 1.1: Proposed mechanism 
Acetylcholine (ACh) is released from endothelial cells in response to shear stress and adenosine 
triphosphate (ATP) is released from erythrocytes in response to deoxygenation or deformation. ACh 
binds to muscarinic (M3) receptors and ATP binds to purinergic (P2Y) receptors on endothelial cells, 
which increases cytosolic Ca2+. The rise in intracellular Ca2+ concentration elicits hyperpolarization ⊝ and production of vasodilatory autacoids. Hyperpolarization spreads to vascular smooth muscle 
cells through gap junctions, where it attenuates sympathetic vasoconstriction by modulating the post-




the endothelium limits sympathetic vasoconstriction in a variety of vascular beds (Behringer & 
Segal, 2012a). Currently, the only vasoactive molecule known to attenuate α-adrenergic 
vasoconstriction when administered exogenously to humans under resting conditions is 
adenosine triphosphate (ATP) (Rosenmeier et al., 2008), which binds to Gq/11 protein-coupled 
receptors (purinergic P2Y receptors) on the endothelium (Fig. 1.1). ACh elicits vascular 
hyperpolarization through a similar Gq/11 protein-coupled receptor-mediated mechanism 
(muscarinic M3 receptors; Fig. 1.1), and application of exogenous ACh to skeletal muscle 
resistance arterioles blunts sympathetic vasoconstriction in rodents (Kurjiaka & Segal, 1995). 
We have observed that intra-arterial infusion of exogenous ACh blunts α1-adrenergic during 
forearm exercise (Hearon et al., 2016, 2017), which suggests a potential role of ACh in vascular 
control within contracting muscle. To date, no study has determined whether endogenous ACh 
contributes to functional sympatholysis in humans.   
Flow-mediated vasodilation  
The ability of the endothelium to facilitate vasodilation in response to vascular wall shear 
stress is a critical component of vascular function. Due to its close association with sensitivity to 
infused ACh, flow-mediated dilation (FMD) of the brachial artery is commonly used as a 
surrogate measure of endothelial function. Interestingly, muscarinic ACh receptor activation 
contributes to basal and flow-induced nitric oxide synthesis and vasorelaxation of coronary 
artery rings superfused with effluent from isolated canine conduit arteries (Martin et al., 1996). 
Together with recent evidence that ACh released from endothelial cells in response to shear 
mediates endothelial calcium signaling and nitric oxide production ex vivo (Wilson et al., 2016), 
these findings suggest that locally-released ACh plays a role in endothelial mechanotransduction 
and flow-mediated dilation.  
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Summary and overall goal 
The vascular endothelium is highly responsive to ACh, and evidence from isolated 
arteries indicates that ACh is synthesized and released from endothelial cells in response to shear 
stress (Martin et al., 1996; Wilson et al., 2016). Interestingly, activation of endothelial cells has 
been shown to amplify the response to additional vasodilatory stimuli (Sonkusare et al., 2014; 
Lee et al., 2018; Hearon et al., 2019), and application of ACh to resistance vessels of resting 
skeletal muscle markedly attenuates sympathetic vasoconstriction in rodents (Kurjiaka & Segal, 
1995). We have recently demonstrated that intra-arterial administration of exogenous ACh 
enhances sympatholysis during mild intensity exercise (Hearon et al., 2016); however, whether 
endogenous ACh is involved in the integrative control of vascular tone in humans is unknown. 
Therefore, the overall goal of this dissertation is to determine the physiological role of 
endogenous ACh in functional sympatholysis and conduit artery flow-mediated dilation in 
humans. 
SPECIFIC AIMS 
Experiment 1: To determine whether combined action of the endothelium-dependent agonists 
ACh and ATP enhances vasodilation and blunts α1-adrenergic vasoconstriction in the forearm 
resistance vasculature. 
Experiment 2: To determine the role of endogenous ACh in functional sympatholysis in 
contracting skeletal muscle. 
Experiment 3: To determine the contribution of endogenous ACh to flow-mediated vasodilation 
of the brachial artery in response to sustained and transient shear stimuli.  
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CHAPTER 2 – MANUSCRIPT 1 
Endothelium-dependent agonists ACh and ATP interact to augment vasodilation 
and limit α1-adrenergic vasoconstriction in human skeletal muscle 
INTRODUCTION 
Vascular tone is regulated in a highly specific manner that relies on integration of 
numerous vasoactive mechanisms. The vascular endothelium constantly monitors physiological 
cues and processes multiple chemical and mechanical stimuli arising from the bloodstream and 
surrounding tissues to regulate vessel diameter. Precisely how the endothelium integrates 
simultaneous sensory inputs to govern an appropriate response is not clear; however, it appears 
to involve complex interactions and communication between neighboring endothelial cells (ECs) 
and underlying vascular smooth muscle cells (VSMCs). 
Activation of the endothelium by physiological stimuli is typically mediated by 
fluctuations in cytosolic Ca2+. Vasodilatory molecules such as adenosine triphosphate (ATP) and 
acetylcholine (ACh) stimulate an increase cytosolic Ca2+ when they bind to their respective 
purinergic (P2Y) and muscarinic (M3) receptors on the endothelium. Likewise, shear forces 
exerted by blood flowing along the endothelium initiate cytosolic Ca2+ signals. In addition to 
stimulating the production and release of vasodilatory autacoids such as nitric oxide and 
prostaglandins, elevated Ca2+ within ECs stimulates Ca2+-activated K+ (KCa) channels. The 
resulting efflux of K+ results in endothelium-derived hyperpolarization, which is conducted to 
adjacent ECs and spreads to underlying VSMCs to promote relaxation.  
Mounting evidence suggests that activation of the endothelium enhances its sensitivity to 
further stimulation. Using freshly isolated arteries from rats, Lee et al. (2018) recently 
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determined that muscarinic and purinergic receptors are heterogeneously distributed among ECs 
such that clusters of ECs detect each agonist and communicate the information with neighboring 
cells to coordinate an appropriate response. When a combination of ATP and ACh is applied to 
the endothelium, a synergistic response occurs with distinct Ca2+ signals that are not observed 
when either dilator is applied in isolation, which suggests that ATP and ACh augment sensitivity 
to each other. Such interactions also appear to affect vasomotor responses. For example, in the 
cutaneous microcirculation, administration of ATP enhances subsequent cholinergic vasodilation 
(Fujii et al., 2015). ATP activates KIR channels, which have been shown to amplify electrical 
signaling in ECs in response to cholinergic vasodilation (Sonkusare et al., 2016); thus, 
circulating ATP could act on the endothelium to enhance its sensitivity to other stimuli. Indeed, 
we recently demonstrated that vasodilation to ACh is selectively amplified in contracting skeletal 
muscle (Hearon et al., 2019) when circulating ATP is elevated (González-Alonso et al., 2002; 
Kirby et al., 2012). Collectively, these observations highlight the ability of the endothelium to 
process complex interactions between multiple signals and evoke an appropriate hemodynamic 
response. 
In addition to sensing circulating vasodilators, the endothelium receives input from and 
communicates with VSMCs to regulate vascular tone. This is particularly important during 
whole-body exercise, when elevated sympathetic nerve activity stimulates α-adrenergic receptors 
on VSMCs to elicit vasoconstriction. Although muscle sympathetic nerve activity is increased 
during exercise, α-adrenergic vasoconstriction is attenuated within the resistance vasculature of 
contracting skeletal muscle, which facilitates redistribution of blood flow to active muscle. This 
phenomenon of “functional sympatholysis” is essential to ensure adequate delivery of oxygen to 
the working muscle despite elevated sympathetic outflow. Although the mechanisms that 
8 
 
attenuate post-junctional α-adrenergic signaling in the microcirculation of exercising muscle are 
unclear, accumulating evidence suggests that the endothelium plays a central role in limiting 
sympathetic vasoconstriction (Kerr et al., 2012). In rodents, endothelium-dependent 
hyperpolarization counteracts sympathetic vasoconstriction (Kurjiaka & Segal, 1995), and in 
humans, activating the endothelium with either ATP or ACh enhances functional sympatholysis  
(Hearon et al., 2016). Thus, the endothelium appears to play a key role in limiting sympathetic 
vasoconstriction; yet it is currently unknown whether endothelium-dependent stimuli interact to 
modulate sensitivity to sympathetic constriction. 
Therefore, in the present study, we aimed to determine whether combined action of the 
endothelium-dependent agonists ATP and ACh elicits greater vasodilation and further limits 
α1-adrenergic vasoconstriction compared to the combined action of either dilator with the 
endothelium-independent dilator SNP.  
METHODS 
Participants and ethical approval 
All experimental protocols were approved by the Institutional Review Board at Colorado 
State University (protocol 14-5392H) and performed in accordance with the Declaration of 
Helsinki except for registration in a database. After providing written, informed consent, 11 
healthy volunteers (5 women, 6 men; 24 ± 0.7 y, 26 ± 2% body fat; means ± SE) completed the 
study. Participants were free from cardiovascular and metabolic disease and were not taking any 
medications aside from oral contraceptives (3 participants).  
Instrumentation 
Participants arrived at the laboratory at 7 AM following an overnight fast and lay supine 
with the non-dominant arm abducted 90 degrees resting on a table slightly above heart level 
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throughout the study visit. After local anesthesia (1% lidocaine), a 20 g, 7 cm catheter was 
inserted in the brachial artery using sterile technique. The catheter was continuously flushed with 
heparinized saline and connected to a 3-way port for infusion of vasoactive drugs. Mean arterial 
pressure (MAP) was determined using a pressure transducer connected to the catheter and heart 
rate (HR) was assessed with a three-lead electrocardiogram (Cardiocap/5). Studies were 
conducted in a temperature-controlled room with a fan directed at the experimental arm to 
minimize skin blood flow. 
Forearm blood flow 
Forearm blood flow was determined using Doppler ultrasound. Brachial artery blood 
velocity and diameter were measured proximal to the catheter using a 12 MHz linear array 
ultrasound probe (Vivid7, General Electric, Milwaukee, WI). Velocity was measured with a 
probe insonation angle <60° at a frequency of 5 MHz, and a spectral analyzer (Multigon 500 M, 
Multigon Industries, Mount Vernon, NY) was used to determine mean blood velocity (MBV) as 
the weighted mean of the spectrum of Doppler shift frequencies. Brachial artery diameter was 
measured at end-diastole at 30 s intervals throughout each trial from images recorded on a DVD. 
Forearm blood flow (FBF) was calculated as FBF = MBV × π × (diameter ÷ 2)2 and expressed in 
ml/min and forearm vascular conductance (FVC) was calculated as FVC = FBF ÷ MAP × 100 
and expressed in ml/min/100 mmHg.  
Endothelium-dependent and independent vasodilation 
All vasoactive drugs were infused through the arterial catheter at low inflow rates 
(approximately 2 ml/min) to elicit local effects within the experimental forearm without affecting 
central hemodynamics. Doses were adjusted according to each participant’s forearm volume 
(FAV) determined by dual X-ray absorptiometry.  
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Adenosine triphosphate (ATP; A7699, Sigma-Aldrich, St. Louis, MO, USA) and 
acetylcholine (ACh; Miochol-E, Novartis, Basel, Switzerland) were used to stimulate 
endothelium-dependent vasodilation and sodium nitroprusside (SNP; Hospira, Lake Forest, IL, 
USA) was used to stimulate direct vascular smooth muscle relaxation that occurs independently 
of the endothelium. Each drug was infused at a low dose with the intention of elevating FBF to 
approximately 3 times baseline FBF. ATP was infused at 1.28 μg/dl FAV/min in all participants, 
and the doses of ACh and SNP were adjusted to elicit similar steady-state vasodilation to that 
observed during ATP. Initially, doses of 1.50 μg ACh/dl FAV/min and 0.20 μg SNP/dl FAV/min 
were used; however, in subsequent participants, the doses were adjusted to better match average 
steady-state vasodilation (ACh, 1.48 ± 0.01, range: 1.36 – 1.50 μg/dl FAV/min; SNP, 0.28 ± 
0.02, range: 0.18 – 0.35 μg/dl FAV/min). Due to time constraints, it was not possible to precisely 
match the response to each dilator within individual participants. However, the same dose of 
each dilator was used for the single dilator and combination trials (described below) within each 
participant.  
Sympathetic α1-adrenergic vasoconstriction 
To assess sensitivity to sympathetic stimulation, the α1-adrenergic receptor agonist 
phenylephrine (PE) was infused via the arterial catheter at 0.125 μg/dl FAV/min. The rate of PE 
was adjusted according to FBF in order to carefully control the sympathetic stimulus, as 
described previously (Dinenno & Joyner, 2003). 
Experimental protocol 
Figure 2.1 illustrates the general experimental protocol (A) and timeline for each trial 
(B). Vasodilation and α1-adrenergic vasoconstrictor sensitivity were assessed during infusion of 
endothelium-dependent (ATP and ACh) and endothelium-independent (SNP) dilators alone and 
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in combination. Initially, the response to each dilator was evaluated separately in randomized 
order, then the following combinations were tested in randomized order: 1) ATP + ACh, 2) SNP 
+ ACh, and 3) SNP + ATP.  
 
Single dilator trials 
In each trial, baseline hemodynamics were assessed during 2 min of saline infusion, then 
the onset of vasodilation was recorded over the initial 3 min of dilator infusion. Steady-state 
2nd dilator (ACh or SNP)
PE
1st dilator (ATP or SNP)
0 2 4 6 8 10 12
SS1 Onset SS2 SSPEBaseline
Dilator (ATP, ACh, or SNP)
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0 2 4 6 8Trial Time (min)
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Figure 2.1: Experimental protocol.  
A) Following brachial artery catheterization, vasodilation and α1-adrenergic vasoconstrictor 
sensitivity were assessed during infusion of endothelium-dependent (ATP, ACh) and 
endothelium-independent (SNP) dilators alone and in combination in trials separated by ≥ 10 
min. B) When each dilator was infused separately, baseline values were recorded, then the onset 
of vasodilation was assessed for 3 min. After steady-state (SS) measurements were obtained, the 
vasoconstrictor response to PE infusion was assessed with steady-state measurements at 2 min of 
PE infusion (SSPE). In the dilator combination trials, the first dilator was infused for 3 min to 
achieve steady-state vasodilation (SS1), then the second dilator was co-infused. The onset of 
vasodilation to the second dilator was recorded for 3 min, after which steady-state (SS2) 
measurements were obtained and PE was infused for 2 min. ATP, adenosine triphosphate; ACh, 




hemodynamics were assessed from minutes 3-4, then PE was infused for 2 min and 
hemodynamics were measured in the final 30 s of the trial. The dose of PE was adjusted 
according to FBF to match the concentration of PE in the blood across trials, as described 
previously by our laboratory  (Kirby et al., 2008, 2011). 
Combination trials 
Baseline hemodynamics were recorded during 2 min of saline infusion prior to each trial, 
after which the first dilator was infused for 4 min to obtain steady-state values. The second 
dilator was then co-infused and the onset of vasodilation to the second dilator was assessed over 
3 min. Following steady-state measurements of combined dilator infusion, PE was infused for 2 
min and hemodynamics were measured in the final 30 s of the trial.  
High SNP trial 
Because we hypothesized that vasodilation would be augmented during combination of 
two endothelium-dependent dilators (ATP + ACh) compared to combination of either dilator 
with SNP (ATP + SNP and SNP + ACh), an additional trial was performed in which a high dose 
of SNP (2.52 ± 1.8 μg/dl FAV/min) was used to elicit vasodilation comparable to that observed 
in the ATP + ACh trial. The purpose of this trial was to serve as a “high flow” control condition 
to better assess vasoconstrictor sensitivity to PE.  
Data acquisition and analysis 
Data were collected at 250 Hz and stored on a computer for analysis with signal 
processing software (Windaq; DATAQ Instruments). Baseline hemodynamics reflect 30 s 
average values immediately preceding the start of dilator infusions. The onset of vasodilation 
was assessed in 3 s bins throughout the initial 3 min of infusion, and steady-state hemodynamics 
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reflect 30 s average values obtained between minutes 3 and 4 of each dilator infusion. Because 
we were limited in our ability to precisely match the hyperemic response to individual dilators 
within each participant, steady-state hemodynamics varied within participants prior to infusion of 
the second dilator. Therefore, vasodilatory responses were expressed as the absolute change in 
FVC from baseline (single dilator trials) or the first dilator (combination trials). Hemodynamics 
during PE reflect 30 s average values at the end of 2 min of PE infusion. Vasoconstrictor 
sensitivity to PE was calculated as (FVCPE – FVCPre-PE) ÷ FVCPre-PE × 100 and expressed as the 
percent change in FVC.  
Statistics 
All values are presented as means ± SE. Baseline hemodynamics prior to each trial were 
compared using one-way, repeated measures ANOVA. The onset of vasodilation was compared 
using two-way, repeated-measures ANOVA (drug × time) of 15 s time-binned averages. Steady-
state responses to each dilator were compared using one-way, repeated-measures ANOVA, and 
hemodynamics before and after PE were compared using two-way, repeated-measures ANOVA 
(drug × condition: pre vs. post PE). Sensitivity to α1-adrenergic vasoconstriction was compared 
with one-way, repeated-measures ANOVA. Tukey’s post-hoc testing was performed when 
appropriate based on significant main effects or interactions between factors. In the event of a 
non-normal distribution, data were log transformed for analysis. All comparisons were 
performed using R statistical software, and significance was evaluated as P < 0.05.  
RESULTS 
Onset and steady-state vasodilation 
Resting hemodynamics were similar prior to the start of all trials (Table 2.1). The time 
course of dilation when each dilator was infused individually is presented in Fig. 2.2A & C. 
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Infusion of ATP or ACh caused rapid vasodilation that peaked within 60-75 s, then declined until 
reaching a steady-state plateau. Vasodilation to SNP occurred more slowly and reached a plateau 
by ~105 s.  As intended, steady-state vasodilation was similar with each dilator (Figs. 2.2A & C 
and 3A).  
Table 2.1: FVC at baseline and during the first 
dilator 
 FVC (ml/min/100 mmHg) 
 Baseline First Dilator  
Single Dilator Trials 
ATP 23 ± 2 — 
ACh 21 ± 1 — 
SNP 23 ± 1 — 
Combination Trials 
ATP + ACh 21 ± 2 65 ± 7* 
SNP + ACh 23 ± 2 73 ± 10* 
ATP + SNP 21 ± 2 64 ± 4* 
High SNP 21 ± 2 — 
Values are means ± SE. Statistical comparisons were 
performed using one-way and two-way (drug × 
time), repeated-measures ANOVA. FVC, forearm 
vascular conductance. *P < 0.05 vs. baseline 
within trial. 
 
In the combination trials, steady-state hemodynamics for were similar during 
administration of the first dilator (Table 2.1). However, because sensitivity to each dilator varied 
within individual participants, FVC was not precisely matched during the first dilator within each 
participant. Therefore, vasodilation was assessed as the change in FVC from the first dilator. The 
onset of vasodilation when the second dilator was co-infused is presented in Fig. 2.2B and D. 
Combination of the two endothelium-dependent dilators (ATP + ACh) caused a steady rise in 
FVC and resulted in sustained vasodilation that was greater than combination of either dilator 
with SNP (Figs. 2.2B & D and 2.3B). In the SNP + ACh trial, addition of ACh resulted in a rapid 
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peak at 45 s; however, vasodilation was temporary and FVC gradually declined toward baseline 
over the course of 3 min. In the ATP + SNP trial, addition of SNP resulted in a slow onset of 
vasodilation that reached a plateau by ~2 min.  
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Figure 2.2: Onset of vasodilation.  
ATP and ACh each evoked rapid vasodilation when administered separately (A & C), whereas the 
onset of vasodilation to SNP occurred more slowly. By 105 s of dilator infusion, Δ FVC was 
similar between trials (C). The onset of vasodilation upon co-infusion of a second dilator is 
shown in panels B & D. The combination of two endothelium-dependent dilators (ATP + ACh) 
caused sustained vasodilation that was greater than combination of either dilator with SNP from 
105 s onward. In contrast, combination of SNP + ACh evoked rapid vasodilation that peaked at 
45 s, then declined toward baseline, whereas combination of ATP + SNP resulted in a slow onset 
of vasodilation at a lesser degree than ATP + ACh (D). Data represent means ± SE for n = 11 
participants (5 women, 6 men). FVC, forearm vascular conductance. * P < 0.05 ATP vs. SNP; + 
P < 0.05 ACh vs. SNP; $ P < 0.05 ATP vs. ATP; † P < 0.05 ATP + ACh vs. SNP + ACh; # P < 




Sympathetic α1-adrenergic vasoconstriction 
Vasoconstrictor sensitivity to PE during the individual dilator trials is presented in Fig. 
2.4A & C. Steady-state FVC was similar during infusion of each dilator prior to administration of 
PE (Fig. 2.4A). The vasoconstrictor response to PE was greater in the SNP trial compared to 
ATP or ACh (Fig. 2.4A & C).  
Vasoconstrictor sensitivity to PE during the combination dilator trials is presented in Fig. 
2.4B & D. Prior to administration of PE, steady-state FVC was greater in the ATP + ACh trial 
compared to other trials. Administration of PE reduced FVC to a similar level during infusion of 
SNP + ACh, ATP + SNP, and High SNP, whereas vasoconstriction was attenuated when the 









































































Figure 2.3: Steady-state vasodilation.  
Each dilator evoked similar vasodilation when administered 
separately (A). Combination of the endothelium-dependent dilators 
ATP + ACh resulted in greater vasodilation than combination of 
either dilator with SNP (B). Data represent means ± SE for n = 11 





The present study was designed on the premise that the vascular endothelium 
simultaneously processes numerous stimuli and integrates information in a complex manner to 
elicit an appropriate vasomotor response. We tested the hypotheses that stimulating the 
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Figure 2.4: Endothelium-dependent dilators combine to attenuate α1-adrenergic constriction.  
When administered separately, ATP and ACh limited vasoconstriction to PE compared to SNP 
(A & C). Steady-state FVC was higher during combination of ATP + ACh compared to other 
trials (B) and combination of the endothelium-dependent dilators limited vasoconstriction to PE 
compared to other combinations or High SNP (D). Sensitivity to α1-adrenergic vasoconstriction 
was further reduced during combination of ATP + ACh (D) than when either dilator was 
administered alone (C). Data represent means ± SE for n = 11 participants (5 women, 6 men). 




limit α1-adrenergic vasoconstriction compared to the combined action of either dilator with SNP, 
which acts directly on vascular smooth muscle. The results demonstrate that endothelium-
dependent agonists interact to augment vasodilation and attenuate α1-adrenergic 
vasoconstriction, whereas such interactions do not occur when either agonist is paired with an 
endothelium-independent vasodilator. These findings highlight the unique capacity of the 
endothelium to synthesize inputs from multiple vasoactive stimuli in human skeletal muscle. 
Onset and steady-state vasodilation 
Recent ex vivo evidence revealed a synergistic effect of ATP and carbachol, an ACh 
analogue, to increase the magnitude and alter the time course of Ca2+ signaling within the 
endothelium (Lee et al., 2018); yet, it was previously unknown whether such interactions occur 
or affect vascular tone in human skeletal muscle. Therefore, in the present study, we evaluated 
whether intra-arterial infusion of ATP enhances vasodilatory sensitivity to ACh. The results 
demonstrate that combination of ATP + ACh causes sustained vasodilation that is augmented 
compared to combination of either dilator with SNP (Figs. 2.2D & 2.3B). Interestingly, although 
both ATP and ACh initiate rapid vasodilation that peaks within ~60 s when administered 
separately, the onset of vasodilation to ACh occurred more slowly and lacked the characteristic 
peak when it was co-infused on top of ATP. In contrast, the rapid peak still occurred when ACh 
was co-infused on top of SNP. These findings suggest that ATP interacts with ACh to influence 
the time course and magnitude of vasodilation, which adds to the growing body of evidence that 
stimulating the endothelium heightens its sensitivity to further activation. 
In the combination trials, the response to co-infusion of a second dilator was attenuated 
such that the vasodilatory response to each dilator was not additive when two dilators were 
combined. When administered separately, the dose of each dilator increased FVC by 
19 
 
approximately 50-60 ml/min/100 mmHg (Fig. 2.2A). In contrast, the same dose increased FVC 
by only 20-30 ml/min/100 mmHg when it was infused as the second dilator during the SNP + 
ACh and ATP + SNP trials (Fig. 2.2B). Thus, the vasodilatory response to the second dilator was 
only preserved when two endothelium-dependent dilators were combined during the ATP + ACh 
trial, where FVC increased by an additional ~50 ml/min/100 mmHg (Fig. 2.2B). Although the 
reasons for this are unclear, we speculate that the elevation in blood flow generated by the first 
dilator may have diluted the concentration of the second dilator in the arterial circulation. 
Alternatively, it is possible that the overperfusion of resting tissue relative to its metabolic 
demand may have caused other mechanisms to restrain vasodilation  (Hester et al., 1982; Welsh 
et al., 1998). Therefore, while vasodilation was clearly enhanced during combination of the two 
endothelium-dependent dilators compared to other combinations, we are limited by our approach 
of sequentially adding two dilators.  
Sympathetic α1-adrenergic vasoconstriction 
Accumulating evidence suggests that the endothelium merges inputs from vasodilatory 
stimuli and the sympathetic nervous system to regulate vascular tone (Segal, 2015). In a hamster 
cremaster preparation, hyperpolarization arising from the endothelium limits sympathetic 
vasoconstriction (Kurjiaka & Segal, 1995), and in humans, infusion of ATP reduces sensitivity to 
α-adrenergic agonists (Kirby et al., 2008). These examples of myoendothelial communication 
have important implications for blood flow distribution when sympathetic nerve activity is 
elevated. During whole-body exercise, sympathetic outflow increases to muscle and splanchnic 
circulations; yet, sensitivity to sympathetic vasoconstriction is reduced within the vasculature 
supplying contracting skeletal muscle (Remensnyder et al., 1962). Although the mechanisms 
underlying functional sympatholysis are unknown, we previously demonstrated that stimulating 
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the endothelium with low doses of ATP or ACh enhances sympatholysis in active muscle 
(Hearon et al., 2016). This reflects a specific ability of the endothelium to modulate 
α1-adrenergic vasoconstriction, as similar results are not observed during infusion of SNP or 
KCl, which act directly on vascular smooth muscle to cause vasodilation.  
Therefore, in the present study, we sought to determine whether endothelium-dependent 
agonists interact to further limit α1-adrenergic vasoconstriction. When administered separately, 
ATP and ACh each reduced sensitivity to the α1-adrenergic receptor agonist PE (Fig. 2.4C). 
Combined infusion of ATP + ACh further limited sympathetic vasoconstriction compared to 
either dilator alone (Fig. 2.4C & D; P = 0.03 vs. ATP alone; P = 0.02 vs. ACh alone) or in 
combination with SNP. Indeed, because steady-state vascular conductance was approximately 
2-fold higher during ATP + ACh (Fig. 2.4B) compared to infusion of either dilator alone (Fig. 
2.4A) and sensitivity to PE is assessed as a percentage change, this comparison likely 
underestimates the effects of combined infusion to restrain sympathetic constriction. These 
findings suggest that combined activation of the endothelium enhances its capacity to regulate 
vascular tone through specific interactions with post-junctional α1-adrenergic signaling, which 
further emphasizes the role of the endothelium in integrating information from a multitude of 
inputs.  
Potential cellular signaling mechanisms 
Many chemical and mechanical stimuli that act on the endothelium are transduced as 
localized cytosolic Ca2+ signals which give rise to endothelium-dependent hyperpolarization and 
stimulate production of vasodilatory autacoids. The results of this study indicate an interaction 
between ATP and ACh, which each bind to Gq/11 coupled protein receptors on the endothelium. 
Activation of these receptors mobilizes Ca2+ from both intracellular stores and influx across the 
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cell membrane, and the resulting rise in cytosolic Ca2+ propagates to neighboring ECs, possibly 
by direct exchange of Ca2+ or IP3 via gap junctions or through the spread of hyperpolarization, 
which enhances Ca2+ entry (Behringer & Segal, 2015). Interestingly, ATP and ACh initiate 
distinctive Ca2+ oscillations which are influenced by the presence of the other agonist such that 
combined activation of ATP and ACh receptors generates a new, synergistic Ca2+ signal  (Lee et 
al., 2018). Ultimately, a rise in cytosolic Ca2+ stimulates production of autacoids such as nitric 
oxide and prostaglandins and opens Ca2+-activated K+ (KCa) channels. Release of K+ through 
these channels initiates hyperpolarization that spreads through gap junctions to adjacent ECs and 
VSMCs, where it activates inwardly-rectifying (KIR) channels to further efflux K+ and boost the 
electrical signal. In the end, hyperpolarization of vascular smooth muscle inhibits entry of Ca2+ 
through voltage-gated Ca2+ channels to promote relaxation and vasodilation.  
The cellular signaling mechanisms by which ATP and ACh interact to augment 
vasodilation and limit α1-adrenergic vasoconstriction are unclear. Further, it is important to note 
that the effects on vasodilation and sympathetic constriction may be mediated by different 
mechanisms. Membrane potential hyperpolarization enhances Ca2+ entry in ECs in response to 
ACh  (Behringer & Segal, 2015), and augmented Ca2+ signaling like that reported in the rat 
carotid endothelium during combined application of ATP + ACh could increase vasodilation 
through several mechanisms, including electrical signaling and release of autacoids. Activation 
of KIR channels amplifies hyperpolarization, and we and others have observed that KIR channels 
enhance endothelium-dependent vasodilation in a variety of circumstances (Rivers et al., 2001; 
Smith et al., 2008; Sonkusare et al., 2016; Hearon et al., 2019). In contrast to the wide array of 
mediators which could enhance vasodilation, the ability of the endothelium to limit sympathetic 
vasoconstriction appears to be more specific. Indeed, the sympatholytic properties of ATP 
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remain intact even during combined inhibition of KIR channels, the Na+/K+-ATPase, and 
synthesis of nitric oxide and prostaglandins (Hearon et al., 2017), which is in line with other 
observations that these pathways are not required for sympatholysis (Crecelius et al., 2015; 
Hearon et al., 2016). In rodent vessels, conducted vasodilation in response to endothelial 
stimulation opposes sympathetic vasoconstriction (Kurjiaka & Segal, 1995), and the conducted 
vasodilatory responses to ATP and ACh are mediated by activation of small- and intermediate-
conductance KCa channels (Marchenko, 2002; Winter & Dora, 2007). Collectively, augmented 
Ca2+ signaling in response to combination of ATP + ACh coupled with the dense localization of 
KCa at myoendothelial projections (Ledoux et al., 2008) points toward involvement of KCa-
mediated electrical signaling in the ability of the endothelium to modulate sympathetic 
vasoconstriction. 
Implications for blood flow regulation 
Interactions involving ATP and ACh may have physiological relevance for controlling 
peripheral vascular tone. Endothelial cells and erythrocytes release ATP in response to 
deoxygenation and mechanical forces such as shear stress and deformation  (Milner et al., 1990; 
Faris & Spence, 2008; Wang et al., 2015); thus, ATP serves as a vasodilatory signal in areas with 
low tissue PO2 to help match O2 delivery with metabolic demand (Ellsworth et al., 2016). In 
humans, circulating levels of ATP are elevated during hypoxia and muscle contractions 
(González-Alonso et al., 2002; Kirby et al., 2012), which may serve to enhance the 
endothelium’s sensitivity to further stimuli. In support of this idea, ATP potentiates flow-
mediated vasodilation in isolated rat mesenteric arteries; indeed, the presence of ATP is required 
for sustained dilation in response to shear (Liu et al., 2004). Likewise, an increase in flow rate 
enhances vasodilatory sensitivity to ATP. Although it is not clear whether endogenous ACh 
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plays a physiological role in blood flow regulation in humans (Joyner & Dietz, 2003), studies of 
cultured endothelial cells and isolated arteries suggest that endothelial cells synthesize and 
release ACh in response to shear stress to facilitate flow-mediated vasodilation (Milner et al., 
1990; Martin et al., 1996; Wilson et al., 2016). We have observed that infusion of exogenous 
ACh amplifies vasodilation in response to exercise (Hearon et al., 2019), and both ATP and ACh 
augment functional sympatholysis within contracting muscle in humans (Hearon et al., 2016).  
The results of the present study indicate that activating the endothelium with multiple 
agonists enhances vasodilation and limits sympathetic vasoconstriction, which may have 
profound implications for blood flow regulation under physiological conditions. Interactions 
between vasoactive stimuli may enable the endothelium to effectively process several inputs and 
coordinate an appropriate response to regulate blood flow distribution. Indeed, the results of this 
study and others suggest that the presence of multiple stimuli may alter the threshold for eliciting 
an endothelium-dependent vasodilatory response (Liu et al., 2004; Lee et al., 2018; Hearon et 
al., 2019). This may be particularly important during physiological stressors such as exercise and 
hypoxia, when a number of stimuli act in concert to regulate skeletal muscle blood flow. 
Moreover, the observation that endothelium-dependent agonists combine to limit α1-adrenergic 
vasoconstriction provides insight regarding the mechanisms of functional sympatholysis, as a 
number of stimuli act on the microcirculatory endothelium within contracting skeletal muscle 
that may serve to attenuate sympathetic vasoconstriction. Further experiments will be required to 





Due to time constraints, we were unable to precisely match the response to each dilator 
within individual participants. Thus, although each dilator caused similar vasodilation when 
assessed as a group average response, this was not always the case for individual participants. As 
a result, steady-state FVC varied during infusion of the first dilator in combination trials. 
Therefore, we assessed vasodilation to the second dilator as the absolute change in FVC to 
account for baseline differences. Our inability to carefully match vasodilation for each 
participant is a clear limitation that likely increased the variability of the results; nonetheless, the 
findings support the conclusion that endothelium-dependent agonists combine to promote greater 
vasodilation than is observed during combination with a direct smooth muscle dilator. 
The present investigation was limited to three vasodilatory substances and one 
vasoconstrictor. Moreover, vasodilators were always infused in the same order during the 
combination trials. It is therefore unclear whether the interactions we observed between ATP and 
ACh also occur with other endothelium-dependent vasodilators, such as bradykinin and 
substance P, or whether the same interactions would occur if the order of dilators was reversed. 
Similarly, it is unclear whether combined activation of the endothelium also affects 
vasoconstriction mediated by other mechanisms, such as angiotensin II, endothelin, or 
α2-adrenergic receptors. In rodent preparations, the distribution of receptors and sensitivity to 
many of these agonists is heterogeneous among neighboring endothelial cells (Tomlinson et al., 
1991; Marie & Bény, 2002), which is comparable to the distinct clusters of cells that respond to 
ATP or ACh (Lee et al., 2018). Thus, we speculate that cellular characteristics such as the 
distribution of surface receptors and gap junctions within a population of endothelial cells and 
across different circulatory beds determine how various vasoactive stimuli interact. Ultimately, 
while we designed the present study to assess the role of endothelium-dependent vs. 
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endothelium-independent vasodilation, our interpretation is limited to interactions between the 
specific dilators we employed in the human forearm circulation. 
Perspectives 
Many patient populations at elevated risk for cardiovascular disease display both 
endothelial dysfunction and elevated sympathetic nervous system activity. Thus, understanding 
the interactions between vasodilator and vasoconstrictor signaling may lead to strategies to 
improve tissue blood flow and oxygen delivery in at-risk populations (Saltin & Mortensen, 
2012). We have observed impairments in ATP release from erythrocytes of older adults which 
correspond to reductions in circulating ATP during exercise and systemic hypoxia (Kirby et al., 
2012). Therefore, therapeutic approaches to enhance circulating ATP in older adults (Racine & 
Dinenno, 2019) could potentially improve vasodilatory sensitivity to shear stress or ACh, which 
decline with age (Celermajer et al., 1994; Gerhard et al., 1996), while also improving the 
capacity to overcome exaggerated sympathetic activation. 
CONCLUSIONS 
The present study was designed to investigate potential interactions between 
endothelium-dependent vasodilators and sympathetic vasoconstriction. The findings demonstrate 
that the endothelium-dependent agonists ATP and ACh combine to augment vasodilation 
compared to that observed when either agonist is paired with the endothelium-independent 
dilator SNP, which suggests that activation of the endothelium enhances its sensitivity to further 
stimuli. In addition to augmenting vasodilation, the combination of ATP and ACh attenuates 
α1-adrenergic vasoconstriction in resting skeletal muscle, which has implications for functional 
sympatholysis. Collectively, these observations highlight the endothelium as a key site for 
integrating multiple vasoactive inputs to efficiently regulate tissue blood flow. Yet, how such 
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interactions occur to regulate vascular tone in humans under physiological conditions remains to 
be determined.  
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CHAPTER 3 – MANUSCRIPT 2 
Endogenous ACh limits α1-adrenergic vasoconstriction in 
contracting skeletal muscle of humans 
INTRODUCTION 
The hemodynamic response to whole-body exercise entails an increase in sympathetic 
nervous system activity that serves to increase cardiac output and regulate systemic vascular 
resistance. Sympathetic vasoconstriction limits blood flow to inactive tissues, which facilitates 
redistribution of blood to metabolically-active skeletal muscle without compromising arterial 
blood pressure. Although elevated sympathetic outflow is also directed toward active skeletal 
muscle, α-adrenergic vasoconstriction is dramatically attenuated within the vasculature of 
contracting muscle (Remensnyder et al., 1962). This ability of working skeletal muscle to limit 
sympathetic vasoconstriction, termed ‘functional sympatholysis,’ is essential to ensure adequate 
blood flow to the active muscle. In older adults and some patient populations, the ability of 
working muscle to modulate sympathetic constriction becomes impaired (Koch et al., 2003; 
Dinenno et al., 2005; Vongpatanasin et al., 2011), which restricts oxygen consumption, increases 
blood lactate, and elevates arterial pressure (Mortensen et al., 2012). Thus, elucidating the 
signaling mechanisms that underlie functional sympatholysis is an important goal with 
implications for exercise intolerance in aging and clinical populations (Saltin & Mortensen, 
2012).  
The mechanisms that modulate post-junctional α-adrenergic signaling within active 
skeletal muscle remain poorly understood (Saltin & Mortensen, 2012). A variety of substances 
including nitric oxide, prostaglandins, and potassium have been proposed as potential mediators 
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of functional sympatholysis (Rosenmeier et al., 2003; Dinenno & Joyner, 2004; Keller et al., 
2004; Crecelius et al., 2015); yet the signaling pathways capable of blunting sympathetic 
constriction in humans have been challenging to elucidate. To date, no study employing 
pharmacological inhibition to investigate potential mechanisms in humans has clearly impacted 
the ability of contracting muscle to blunt sympathetic vasoconstriction (Rosenmeier et al., 2003; 
Dinenno & Joyner, 2004; Keller et al., 2004; Crecelius et al., 2015). Indeed, functional 
sympatholysis remains intact even during combined inhibition of nitric oxide, vasodilatory 
prostaglandins, inwardly-rectifying potassium channels, and the sodium/potassium pump 
(Crecelius et al., 2015).  
Thus, our current understanding relies on studies which have employed exogenous 
administration of vasoactive molecules to mimic functional sympatholysis. Mounting evidence 
from these studies suggests that the vascular endothelium is a critical site for integration of local 
vasodilatory and sympathetic vasoconstrictor signaling (Behringer & Segal, 2012b; Kerr et al., 
2012; Hearon et al., 2016; Terwoord et al., 2017), and evidence from experimental animals 
suggests that hyperpolarization originating in the endothelium limits sympathetic 
vasoconstriction in a variety of vascular beds (Behringer & Segal, 2012b). In rodents, application 
of the endothelium-dependent vasodilator acetylcholine (ACh) elicits vascular hyperpolarization 
and blunts sympathetic vasoconstriction in skeletal muscle resistance arterioles (Kurjiaka & 
Segal, 1995), and in humans, intra-arterial infusion of ACh enhances functional sympatholysis 
during mild intensity exercise (Hearon et al., 2016).  
Collectively, these observations suggest a potential role of ACh in vascular control within 
contracting muscle. Therefore, in the present study, we tested the hypothesis that endogenous 
ACh contributes to functional sympatholysis in humans. The results indicate that muscarinic 
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ACh receptors modulate α1-adrenergic vasoconstriction during heavy intensity exercise, 
demonstrating a novel, functional role of ACh receptors in the peripheral vasculature in humans. 
METHODS 
Participants and ethical approval 
All experimental procedures were approved by the Institutional Review Board at 
Colorado State University (protocol 14-5392H) and performed in accordance with The 
Declaration of Helsinki except for registration in a database. Sixteen healthy volunteers (8 
women, 8 men; 26 ± 1 y; 25 ± 2% body fat; means ± SE) completed the study after providing 
written, informed consent. Participants were free from cardiovascular disease and reported the 
following medications: levothyroxine and a selective serotonin reuptake inhibitor (1 participant) 
and oral contraceptives (4 participants). 
Instrumentation 
Participants arrived at the laboratory in the morning following an overnight fast. Studies 
were performed in a cool (19-20°C), temperature-controlled laboratory where participants lay 
supine with the experimental (non-dominant) arm abducted 90° and supported slightly above 
heart level. Following local anesthesia with 2% lidocaine, a 20 g, 7 cm catheter was introduced 
to the brachial artery using sterile technique. The catheter was continuously flushed with 
heparinized saline and connected to a 3-way port for local drug administration. Heart rate (HR) 
was monitored with a 3-lead ECG (Cardiocap/5) and arterial pressure was continuously recorded 
with a transducer connected to the catheter. A fan was directed at the experimental forearm 
throughout the study to minimize skin blood flow.  
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Forearm blood flow and vascular conductance 
Brachial artery diameter and blood velocity were measured with a 12 MHz linear array 
Doppler ultrasound probe (Vivid7, General Electric, Milwaukee, WI) proximal to the catheter to 
measure forearm blood flow (FBF). Beat-by-beat velocity was measured at a frequency of 5 
MHz using an insonation angle of 60° and mean blood velocity (MBV) was determined as the 
weighted mean of the spectrum of Doppler shift frequencies (Multigon 500 M, Multigon 
Industries, Mount Vernon, NY). Diameter was measured in triplicate at end-diastole and FBF 
was calculated as FBF = π × (diameter ÷ 2)2 × MBV and expressed in ml/min. Forearm vascular 
conductance (FVC) was evaluated as an index of vascular tone. FVC was calculated as FVC = 
FBF ÷ MAP × 100 and expressed in ml/min/100 mmHg. 
Rhythmic handgrip exercise 
Participants performed dynamic handgrip contractions to lift a weight connected to a 
pulley system. The weight corresponded to 15 or 25% of the participant’s maximal voluntary 
contraction force (MVC; see experimental design below) and was lifted 4-5 cm at a rate of 20 
contractions per minute (1 s contraction followed by 2 s relaxation).  
Vasoactive drug administration 
All drugs were infused through the arterial catheter at low flow rates (approximately 2 
ml/min) to cause local effects within the forearm without altering systemic hemodynamics. Each 
participant’s forearm volume (FAV) was determined prior to the study using dual X-ray 




In the resting trial, adenosine or sodium nitroprusside was infused as a control vasodilator 
intended to match steady-state hyperemia to that observed during exercise at 15% MVC (see 
Experimental Protocol). Adenosine and sodium nitroprusside were selected because they do not 
exhibit sympatholytic properties in our laboratory (Kirby et al., 2008; Crecelius et al., 2015; 
Hearon et al., 2016). Based on drug availability, six participants (4F, 2M) received adenosine 
with a final dose of 19 ± 7 µg/dl FAV/min and five participants (2F, 3M) received sodium 
nitroprusside with a final dose of 4.8 ± 0.3 µg/dl FAV/min.  
Sympathetic α1-adrenergic vasoconstriction 
To evaluate sympathetic vasoconstrictor sensitivity, phenylephrine (PE, α1 agonist) was 
infused at a dose of 0.125 µg/dl FAV/min. In an effort to normalize the concentration of PE in 
the arterial inflow, the rate of PE was adjusted according to forearm blood flow, as described 
previously (Dinenno & Joyner, 2003).  
ACh dose-response 
The response to infusion of exogenous ACh was assessed under control conditions and 
following inhibition of muscarinic ACh receptors to determine blockade efficacy. ACh was 
infused at doses of 4, 8, and 16 µg/dl FAV/min for 3 min per dose.  
Muscarinic ACh receptor blockade 
Following control trials, atropine (muscarinic ACh receptor antagonist) was infused to 
inhibit ACh receptors. Initially, a total of 0.2 mg was administered over the course of 3 min as a 
loading dose (Shoemaker et al., 1997; Brock et al., 1998). Prior to subsequent trials, an 
additional 0.07 mg was infused over 1 min as a maintenance dose. Infusion of atropine always 
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occurred as a bolus dose approximately 2 min before the start of each trial; atropine was not 
continuously infused during exercise or vasodilator administration.   
Experimental protocol 
An overview of the experimental protocol is shown in Figure 3.1. To determine the role 
of ACh in functional sympatholysis, we evaluated sensitivity to α1-adrenergic vasoconstriction at 
rest and during rhythmic handgrip exercise under control conditions and following local 
inhibition of muscarinic ACh receptors.  
Because sympatholysis is graded with exercise intensity, we assessed sympathetic 
vasoconstriction during both moderate (15% MVC) and heavy (25% MVC) intensity handgrip 
exercise. In the resting trial, we infused a vasodilator (adenosine or sodium nitroprusside) to 
match forearm blood flow to that observed during 15% MVC exercise; this served as a “high 
flow” control condition to compare sympathetic vasoconstriction from a similar starting level of 
hyperemia. At the beginning of each trial, baseline data were collected for 2 min, then the 
hyperemic condition (dilator infusion or forearm exercise) began (Fig. 3.1A). Steady-state 
hemodynamics were assessed at 4 min of dilator infusion or exercise, then PE was infused for 2 
min. Data reflect 30 s of steady-state measurements at the end of each time point (baseline, pre-
PE, and PE).  
Following control trials, muscarinic ACh receptors were blocked with intra-arterial 
atropine and trials were repeated. The response to graded doses of exogenous ACh was evaluated 
under control conditions and following atropine to determine blockade efficacy. All trials were 
separated by ≥ 10 min and the order of trials was counterbalanced across participants.  
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Data acquisition and analysis 
Data were recorded at 250 Hz and stored on a computer for later analysis with signal 
processing software (Windaq; DATAQ Instruments). Hemodynamic values reflect 30 s of 
steady-state measurements as illustrated in Fig. 3.1. Sensitivity to α1-adrenergic vasoconstriction 
was calculated as the PE-mediated change in FVC and expressed as a percentage of FVC prior to 
PE infusion: Δ FVCPE (%) = (FVCPE – FVCSS) ÷ FVCSS × 100.  
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Figure 3.1: Experimental protocol.  
An overview of the study timeline is shown in A. Sympathetic vasoconstrictor sensitivity 
was assessed during separate trials at rest and during handgrip exercise at 15 and 25% 
MVC; the timeline for each trial is illustrated in B. Participants performed rhythmic 
handgrip exercise for 4 min to assess steady-state hemodynamics, then PE (α1-adrenergic 
agonist) was infused and hemodynamics were assessed again after 2 min. In the resting 
trial, a control vasodilator was infused to match steady-state forearm blood flow to that 
observed during exercise at 15% MVC prior to PE infusion. Sensitivity to infusion of 
exogenous ACh was evaluated in a separate trial. Following control trials, a bolus dose of 
atropine was infused to block muscarinic acetylcholine receptors and trials were repeated. 
Trials were separated by ≥10 min rest and the order of trials within control and atropine 
conditions was counterbalanced across participants. FVC, forearm vascular conductance; 




All values are means ± SE. Many comparisons are possible with this experimental 
design; therefore, we have focused on the most relevant statistical analyses to address our 
hypotheses. All comparisons were performed using R statistical programming. Due to the large 
increase in blood flow as a result of exercise or control dilator infusion, baseline values prior to 
each trial (Table 3.1 & Fig. 3.2) were analyzed separately and compared using two-way (drug × 
trial), repeated-measures ANOVA. Steady-state values during the hyperemic trials (Table 3.1 & 
Fig. 3.2) were compared with three-way (drug × trial × time), repeated-measures ANOVA, and 
vasoconstriction to PE (Fig. 3.3) was assessed with two-way (drug × trial), repeated-measures 
ANOVA. The vasodilatory response to ACh infusion (Fig. 3.4) was compared with two-way 
(drug × ACh dose), repeated-measures ANOVA. Data were log transformed prior to analysis 
when appropriate as a result of non-normal distributions. Statistical significance was determined 
as P < 0.05, and Tukey’s post hoc tests were performed in the event of significant main or 
interaction effects. 
RESULTS 
Sympathetic α1-adrenergic vasoconstriction 
Baseline hemodynamics were similar prior to each trial (Table 3.1 & Fig. 3.2). As 
intended, dilator infusion in the rest trial elevated steady-state FBF and FVC to a level 
comparable to that observed during exercise at 15% MVC (Table 3.1 & Fig. 3.2). Under control 
conditions, infusion of PE reduced FVC to a greater extent at rest compared to during exercise at 
15% or 25% MVC (Fig. 3.2). Sympathetic vasoconstrictor sensitivity was limited in parallel with 
exercise intensity (Fig. 3.3B), indicating functional sympatholysis. Atropine had no effect on 
baseline or steady-state hemodynamics prior to PE in the rest trial or during exercise (Table 3.1 
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& Fig. 3.2). Atropine did not alter sympathetic vasoconstrictor sensitivity at rest or during 
exercise at 15% MVC; however, atropine attenuated functional sympatholysis during exercise at 
25% MVC such that the vasoconstrictor response to PE increased approximately two-fold (Fig. 
3.3).  
Blockade efficacy 
Under control conditions, infusion of exogenous ACh caused robust vasodilation (Fig. 
3.4). Atropine reduced vasodilation to progressive doses of ACh by 66 ± 4, 58 ± 6, and 46 ± 5%. 
DISCUSSION 
The primary observation from the present study is that local inhibition of muscarinic ACh 
receptors with atropine reduces the ability of contracting skeletal muscle to modulate 
α1-adrenergic vasoconstriction, which indicates a key role of ACh as a mechanism of functional 
Table 3.1: Forearm and systemic hemodynamics  
 Control  Atropine 
 Baseline Pre-PE PE  Baseline Pre-PE PE 
Forearm blood flow (ml/min)   
Rest + dilator 27 ± 2 155 ± 18 103 ± 18†‡  29 ± 2 162 ± 19 108 ± 17†‡ 
15% MVC 28 ± 3 179 ± 18 146 ± 13†‡  27 ± 2 190 ± 20 153 ± 16†‡ 
25% MVC 29 ± 3 320 ± 38‡ 295 ± 30‡  32 ± 3  333 ± 36‡ 272 ± 28*†‡ 
Mean arterial pressure (mmHg)   
Rest + dilator 87 ± 2 81 ± 2‡ 84 ± 2†‡  88 ± 2 82 ± 2‡ 85 ± 2†‡ 
15% MVC 88 ± 1 89 ± 2 93 ± 2†‡  89 ± 2 89 ± 1‡ 93 ± 2†‡ 
25% MVC 87 ± 1 94 ± 2 100 ± 3†‡  90 ± 2 95 ± 2‡ 101 ± 3†‡ 
Heart rate (beats/min)   
Rest + dilator 51 ± 2 55 ± 3 54 ± 3  48 ± 2 59 ± 3 53 ± 3 
15% MVC 52 ± 2 57 ± 2 54 ± 2  50 ± 2 54 ± 3 55 ± 3 
25% MVC 50 ± 2 57 ± 2 55 ± 2  53 ± 3 59 ± 3 59 ± 3 
Values are means ± SE. Data were not obtained for each trial in all participants, thus n = 11 for 
rest + dilator, n = 16 for 15% MVC, and n = 15 for 25% MVC. Abbreviations: MVC, maximal 
voluntary contraction; PE, phenylephrine. * P < 0.05 vs. control at same time point; † P < 0.05 




sympatholysis. The results demonstrate that ACh receptors limit sympathetic vasoconstriction 
within active skeletal muscle during exercise at high workloads. This is the first study to reveal 
an essential mechanism of functional sympatholysis, which has important implications for 
understanding the pathophysiology of exercise intolerance in clinical populations. Moreover, the 
results demonstrate a novel, physiological role for ACh in blood flow regulation in humans. 
Potential sources of ACh 
Muscarinic receptors are ubiquitous throughout the peripheral vasculature; indeed, the 
vascular endothelium is so profoundly sensitive to ACh that the vasodilatory response to ACh 
infusion is the gold standard assessment of endothelial function. Yet, despite the close 
association between endothelial dysfunction and cardiovascular disease risk, numerous attempts 










































































Figure 3.2: Forearm vascular conductance responses throughout each trial.  
FVC is presented at baseline, steady-state hyperemia, and during infusion of phenylephrine (PE; 
α1 agonist) for each trial. In the resting trial (A), a control vasodilator was infused to match 
steady-state FVC to that observed during 15% MVC exercise (B) prior to administration of PE. 
Atropine (muscarinic ACh receptor antagonist) did not affect FVC throughout the rest trial (A) or 
15% MVC exercise trial (B). However, during 25% MVC exercise (C), FVC was significantly 
lower during infusion of PE under atropine compared to control conditions. FVC, forearm 




















































































Figure 3.3: Atropine attenuates functional 
sympatholysis at higher exercise intensities.  
The absolute and percent change in FVC in response 
to PE (α1 agonist) are presented in A and B. Under 
control conditions, handgrip exercise progressively 
reduced α1-adrenergic vasoconstriction (B), 
indicating functional sympatholysis. Atropine 
(muscarinic ACh receptor antagonist) did not affect 
sensitivity to PE at rest or during exercise at 15% 
MVC. However, in the 25% MVC exercise trial, PE 
elicited approximately 2-fold greater 
vasoconstriction during atropine compared to 
control conditions. MVC, maximal voluntary 
contraction; PE, phenylephrine. * P < 0.05 vs. 

































Figure 3.4: Atropine blocked vasodilation to 
exogenous ACh.  
Intra-arterial infusion of atropine (muscarinic ACh 
receptor antagonist) successfully inhibited the 
forearm vasodilator response to graded infusions of 
ACh, as intended. ACh; acetylcholine, FAV; 
forearm volume; FVC; forearm vascular 
conductance. * P < 0.05 vs. Control 
 
 (Armstrong & Laughlin, 1986; Buckwalter et al., 1997; Shoemaker et al., 1997; Brock et al., 
1998). Historically, researchers investigated the possibility that ACh was released by 
sympathetic vasodilator nerves (Joyner & Halliwill, 2000; Joyner & Dietz, 2003), as the skeletal 
muscle circulation of many mammalian species is innervated by sympathetic cholinergic fibers 
that serve to increase muscle blood flow when sympathetic outflow is elevated (Bülbring & 
Burn, 1935; Bolme et al., 1970). Initial studies supported this idea by demonstrating atropine-
sensitive forearm vasodilation in response to mental or emotional stress (Blair et al., 1959; Dietz 
et al., 1994); yet, histochemical examination revealed no evidence of sympathetic cholinergic 
nerves in skeletal muscle of humans or other primates (Bolme & Fuxe, 1970; Bolme et al., 
1970). Later, the idea of sympathetic vasodilation was brought into further question when 
sympathetic nerve traffic recordings and stellate ganglion nerve blockade studies revealed that 
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such vasodilatory responses could occur in the absence of muscle sympathetic nerve activity 
(Lindqvist et al., 1996; Halliwill et al., 1997; Reed et al., 2000). Although this is still a topic of 
some debate (Ishii et al., 2013), these studies cast serious doubt on functional innervation of 
human skeletal muscle by sympathetic cholinergic nerves (Joyner & Dietz, 2003). 
Motor neurons have also been investigated as a potential source of ACh that could act on 
the skeletal muscle vasculature. ACh released from motor nerve terminals binds to nicotinic 
receptors at the neuromuscular junction to initiate muscle contractions; thus, spillover of ACh to 
nearby resistance vessels could facilitate concomitant vasodilation in parallel with the degree of 
muscle activation (Fuglevand & Segal, 1997; Welsh & Segal, 1997). Kurjiaka & Segal (1995) 
demonstrated that application of ACh to resistance vessels in the hamster cremaster muscle 
limits vasoconstriction to sympathetic nerve stimulation; thus, they speculated that ACh released 
at the motor end plate could be a mechanism of functional sympatholysis. In a later study, they 
demonstrated that stimulation of motor nerves causes atropine-sensitive vasodilation within the 
cremaster muscle microcirculation even when muscle contractions were prevented via nicotinic 
receptor blockade (Welsh & Segal, 1997). However, Dyke et. al (Dyke et al., 1998) employed a 
similar approach in humans in a subsequent study and reported only minor changes in forearm 
blood flow in response to attempted handgrip contractions following neuromuscular blockade. 
Hellsten and colleagues (2009) expanded on this in a study that employed partial neuromuscular 
blockade such that greater activation of motor neurons (and thus greater release of ACh) was 
required to perform knee extensor exercise at a given workload. Although femoral blood flow 
was enhanced during exercise with the partially paralyzed muscle, inhibition of ACh receptors 
did not alter the response. Furthermore, local inhibition of muscarinic receptors with intra-
arterial atropine does not impact rapid vasodilation following a single muscle contraction in the 
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human forearm (Brock et al., 1998); therefore, the idea that ACh released from motor neurons 
elicits skeletal muscle vasodilation has been largely disregarded. 
The lack of clear evidence for neurogenic vasodilation led many researchers to conclude 
that local cholinergic mechanisms may account for atropine-sensitive changes in blood flow 
observed in human muscle during stressful situations. Cultured endothelial cells release ACh in 
response to shear (Milner et al., 1990), and flow-induced nitric oxide production in isolated 
canine femoral arteries is mediated by ACh (Martin et al., 1996). Recent studies of isolated rat 
carotid and mesenteric arteries demonstrate that endothelial cells synthesize and release ACh in 
response to fluid shear stress and that ACh acts as an autocrine signaling mechanism to stimulate 
nitric oxide production (Wilson et al., 2016).  
Taken together, there is a large body of work investigating sympathetic cholinergic 
nerves, motor nerves, and endothelial cells as potential sources of ACh that could regulate 
muscle blood flow. The experimental approach of the present study does not provide insight to 
the source of ACh; however, because there is no clear evidence of sympathetic vasodilator 
innervation of human skeletal muscle and muscle sympathetic nerve activity does not change 
during rhythmic handgrip exercise (Victor et al., 1987), we do not expect that sympathetic 
cholinergic nerves contributed to our findings. Rather, it is likely that ACh released from 
endothelial cells mediates functional sympatholysis. Additionally, we cannot rule out motor 
nerves as a potential source of ACh, as our observation that sympatholysis is inhibited by 
atropine despite preserved exercise hyperemia suggests that modulation of sympathetic 
vasoconstriction by ACh can occur independent of vasodilation. The specific effect of atropine 
on sympatholysis rather than total blood flow is further discussed in a later section. Ultimately, it 
raises the possibility that ACh released at the neuromuscular junction could limit sympathetic 
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vasoconstriction despite the minor effect of attempted contractions on muscle blood flow 
following muscle paralysis (Dyke et al., 1998).  
Role of ACh in exercise hyperemia 
The results of this study and others indicate that inhibition of muscarinic ACh receptors 
via atropine has little to no effect on muscle blood flow during exercise (Armstrong & Laughlin, 
1986; Buckwalter et al., 1997; Shoemaker et al., 1997; Brock et al., 1998). It is important to note 
that redundant vasodilatory signaling may mask a contribution of endogenous ACh to exercise 
hyperemia, particularly under circumstances that do not elicit an increase in sympathetic outflow 
(Joyner & Wilkins, 2007; Hellsten et al., 2012). In this context, rhythmic handgrip exercise is not 
associated with increased muscle sympathetic nerve activity (Victor et al., 1987). Therefore, 
although the results of the present study demonstrate that endogenous ACh modulates sensitivity 
to sympathetic vasoconstriction in contracting muscle, an obligatory role of endogenous ACh in 
exercise hyperemia may not be revealed by exercise modalities that do not engage the 
sympathetic nervous system. Along these lines, systemic inhibition of ACh receptors partially 
mitigates the fall in peripheral vascular resistance during cycling exercise and completely 
prevents the reduction in systemic vascular resistance during isometric handgrip exercise 
(Vianna et al., 2015), which suggests that ACh contributes to vasodilation during exercise that 
elevates sympathetic outflow.  
In addition, we have observed that not all local vasodilators have sympatholytic 
properties (Hearon et al., 2016), which raises the possibility that ACh is more involved in fine-
tuning the distribution of blood flow within the muscle microcirculation rather than regulating 
bulk blood flow to the tissue (Van Teeffelen & Segal, 2003). Within a contracting muscle, 
sympathetic α-adrenergic vasoconstriction normally restrains blood flow to inactive regions; 
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thus, blood flow is specifically increased to the recruited muscle fibers as a result of functional 
sympatholysis in the most active regions (Heinonen et al., 2012, 2013). Functional 
sympatholysis becomes impaired with advancing age (Dinenno et al., 2002), and the within-
muscle heterogeneity of blood flow distribution is reduced in older men independent of bulk 
tissue blood flow (Rudroff et al., 2014). Maldistribution of blood flow and oxygen delivery 
within the muscle has metabolic consequences: impaired sympatholysis in sedentary older men 
limits tissue oxygen uptake and results in greater lactate release at a given workload compared to 
active older men with preserved sympatholysis despite similar bulk blood flow between groups 
(Mortensen et al., 2012). In support of the idea that ACh may regulate blood flow distribution 
within active muscle, Ishii et al. (Ishii et al., 2013) reported an atropine-induced reduction in 
oxygenated hemoglobin of the vastus lateralis muscle during one-legged cycling exercise. 
Collectively, these studies suggest that the role of ACh in functional sympatholysis may be 
essential for appropriate distribution of blood flow within the exercising muscle independent of 
total exercise hyperemia.  
Mechanisms of functional sympatholysis 
Numerous attempts to pharmacologically inhibit functional sympatholysis in the same 
experimental model have failed to reveal obligatory signaling mechanisms involved in the 
response. Separate inhibition of nitric oxide or prostaglandin synthesis does not alter sympathetic 
vasoconstriction in contracting muscle (Dinenno & Joyner, 2003, 2004), and although combined 
inhibition of these pathways augments α1-adrenergic vasoconstriction in contracting muscle, it 
also augments constriction in quiescent muscle which indicates that the effects are not specific to 
exercise (Dinenno & Joyner, 2004). Similar, non-specific effects are observed during systemic 
inhibition of ATP-sensitive K+ (KATP) channels (Keller et al., 2004). We have observed that 
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inwardly-rectifying K+ (KIR) channels and the Na+/K+-ATPase contribute substantially to 
exercise hyperemia in humans (Crecelius et al., 2014); yet, functional sympatholysis is preserved 
when these vasodilatory pathways are blocked (Crecelius et al., 2015). Indeed, contracting 
skeletal muscle maintains the ability to blunt α1-adrenergic vasoconstriction even during 
simultaneous inhibition of nitric oxide, prostaglandins, KIR channels, and the Na+/K+-ATPase 
(Crecelius et al., 2015). The challenge of elucidating mechanisms involved in functional 
sympatholysis highlights the significance of the observation that atropine increases sympathetic 
vasoconstriction exclusively in contracting skeletal muscle in the present study.  
Potential signaling pathways 
Evidence from animal models suggests that hyperpolarization originating in the 
endothelium limits sympathetic vasoconstriction (Kurjiaka & Segal, 1995; Behringer & Segal, 
2012b), and we have observed that endothelium-dependent agonists capable of eliciting 
hyperpolarization enhance functional sympatholysis in humans (Hearon et al., 2016). ACh binds 
to Gq/11-coupled receptors on the endothelium, which activates phospholipase C and results in 
Ca2+ release from the endoplasmic reticulum as well as Ca2+ entry across the plasma membrane. 
The rise in cytosolic Ca2+ opens Ca2+-activated K+ (KCa) channels, and the resulting efflux of K+ 
hyperpolarizes membrane potential. Ultimately, hyperpolarization spreads from endothelial cells 
to underlying vascular smooth muscle cells, where it inhibits Ca2+ entry via voltage-gated Ca2+ 
channels and thus promotes relaxation.  
In addition to stimulating K+ efflux through KCa channels, ACh initiates downstream 
signaling pathways including enzymatic production of vasodilatory autacoids as well as 
activation of KIR channels and the Na+/K+-ATPase. In this regard, we have observed that 
pharmacological inhibition of nitric oxide and prostaglandin synthesis actually enhances the 
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ability of ACh to blunt α1-adrenergic vasoconstriction (Hearon et al., 2016). Thus, ACh-
stimulated production of vasodilatory autacoids does not appear to contribute to its effects on 
sympathetic vasoconstriction; rather, inhibition of these pathways may cause greater reliance on 
hyperpolarizing mechanisms that modulate sympathetic signaling. We have also demonstrated 
that the sympatholytic effect of exogenous ATP, which binds to similar Gq/11-coupled receptors 
on the endothelium, is intact even during combined inhibition of nitric oxide synthesis, 
prostaglandin synthesis, KIR channels, and the Na+/K+-ATPase (Hearon et al., 2017). Taken 
together with observations that functional sympatholysis is preserved during exercise when these 
pathways are blocked (Crecelius et al., 2015), we speculate that hyperpolarization arising from 
activation of KCa channels is central to the ability of ACh to blunt sympathetic vasoconstriction. 
In a previous study, we demonstrated that ACh interacts with ATP to limit α1-adrenergic 
vasoconstriction in resting muscle such that co-infusion of ACh with ATP mimics the functional 
sympatholysis observed during exercise. We have also observed that the ability of ACh to blunt 
sympathetic vasoconstriction is greatly enhanced by muscle contractions. Indeed, a moderate 
dose (4 ± 2 µg/dl FAV/min) of ACh completely abolishes vasoconstriction to PE during mild 
intensity handgrip exercise, whereas substantial constriction still occurs when a much higher 
dose (12 ± 4 µg/dl FAV/min) of ACh is infused at rest in the same participants (Hearon et al., 
2016). These findings raise the possibility that ACh is permissive to other mechanisms involved 
in limiting sympathetic vasoconstriction. In this regard, several lines of evidence suggest that 
ATP may play a key role in functional sympatholysis. ATP is released from erythrocytes and 
endothelial cells in response to deoxygenation and cellular deformation and circulating ATP 
increases with graded exercise intensity. Although we are unable to block ATP receptors to 
confirm a role of ATP in functional sympatholysis, infusion of exogenous ATP blunts 
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α1-adrenergic vasoconstriction in a dose-dependent manner. In isolated vessels, ACh and ATP 
have a synergistic effect to amplify Ca2+ signaling within endothelial cells, which could enhance 
endothelium-dependent hyperpolarization and thus blunt sympathetic vasoconstriction. 
Therefore, we speculate that ACh interacts with other factors associated with muscle 
contractions to facilitate functional sympatholysis.  
Effect of exercise intensity 
The effect of atropine on functional sympatholysis was intensity-dependent such that 
atropine doubled the vasoconstrictor response to PE during high intensity (25% MVC) exercise, 
whereas it did not significantly affect vasoconstriction during exercise at a lower intensity (15% 
MVC). The reasons for this are not entirely clear; however, it is likely that more ACh is released 
during higher workloads as a result of greater shear-mediated release from endothelial cells 
and/or greater spillover from motor nerves. Interestingly, circulating pyruvate levels influence 
the synthesis and release of ACh by endothelial cells (Wilson et al., 2016); thus, greater pyruvate 
release with graded exercise intensity (Henderson et al., 2004) may also contribute to greater 
ACh release. Considering the aforementioned effect of contractions and intra-arterial ATP to 
enhance the sympatholytic effect of exogenous ACh (Hearon et al., 2016), it is also possible that 
ACh interacts with another factor associated with contraction intensity to limit sympathetic 
vasoconstriction.  
Experimental considerations and limitations 
The site of action of drugs infused intra-arterially is unclear and deserves consideration. 
Bolus infusion of atropine in the present study resulted in a substantial but incomplete blockade 
of the vasodilatory response to intra-arterial ACh. However, although atropine is lipophilic and 
able to cross the blood-brain barrier, its diffusion across the vascular wall appears to be limited 
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(Lew et al., 1989); thus, intraluminal infusion of atropine may not inhibit muscarinic receptors at 
other sites where ACh could act, such as the adventitial surface of endothelial cells. This is 
particularly relevant when considering potential sources of ACh that would initially encounter 
the interstitial surface, such as release from nerve terminals or release from the adventitial 
surface of endothelial cells.  
We did not measure ACh in the present study and therefore do not know if circulating 
ACh increased in an exercise-intensity dependent manner. ACh is rapidly degraded and rarely 
detected in plasma, although circulating ACh has been demonstrated through the use of an 
acetylcholinesterase inhibitor (Kawashima et al., 1987). Studies of isolated vessels clearly show 
that ACh released from endothelial cells activates muscarinic receptors (Wilson et al., 2016); 
therefore, we speculate that the role of muscarinic receptors in the present investigation is due to 
activation by ACh. However, it is also possible that mechanical activation of the receptors by 
shear stress or muscle contractions contributes to functional sympatholysis, as many Gq-coupled 
protein receptors exhibit ligand-independent mechanosensitivity (Mederos y Schnitzler et al., 
2008). Furthermore, sensitivity of some Gq-coupled protein receptors to ligand activation is 
enhanced when combined with mechanical stimuli (Mederos y Schnitzler et al., 2008); therefore, 
it is possible that ACh and mechanical stimuli combine to activate muscarinic receptors during 
exercise. 
Due to time constraints, we did not include a second resting control trial where forearm 
blood flow was elevated to match that observed during exercise at 25% MVC. Sensitivity to PE 
was not affected by atropine at rest when forearm blood flow was matched to that observed 
during 15% MVC exercise; yet, it is unknown whether atropine might have affected 
vasoconstrictor sensitivity if flow was further elevated. Although this consideration is relevant 
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because shear stress stimulates ACh release from endothelial cells, infusing a control vasodilator 
at rest to match blood flow at the brachial artery results in different shear patterns throughout the 
vascular tree compared to the shear forces evoked by muscle contractions. Therefore, it is not 
possible to precisely match shear stimuli between resting and exercise conditions. We speculate 
that atropine would not affect α-adrenergic vasoconstriction at rest if forearm blood flow were 
matched to 25% MVC exercise; however, we acknowledge this as a limitation of our study 
design. 
Perspectives 
The results of this study advance our understanding of the basic mechanisms of blood 
flow regulation in humans and lay the foundation for future strategies to improve exercise 
tolerance in aging and clinical populations. Many people at elevated risk for cardiovascular 
complications display both endothelial dysfunction (i.e. reduced sensitivity to ACh) and elevated 
sympathetic nervous system activity. Thus, understanding the interactions between endothelium-
dependent signaling and sympathetic vasoconstriction may lead to ideas to improve tissue blood 
flow and oxygen delivery in at-risk populations. We recently demonstrated that infusion of ACh 
restores functional sympatholysis in older adults (Hearon Jr. et al., 2020), which suggests that the 
downstream signaling pathways by which ACh modulates α1-adrenergic constriction remain 
intact in older adults. Therefore, therapeutic approaches that enhance ACh release or sensitivity 
have potential to improve peripheral blood flow regulation and oxygen delivery by enhancing 
functional sympatholysis. 
CONCLUSIONS 
Sympathetic vasoconstriction is dramatically attenuated within the vasculature of 
contracting skeletal muscle. This phenomenon of functional sympatholysis is imperative for 
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redistribution of blood flow to active muscle during exercise. The present study demonstrates 
that muscarinic ACh receptors powerfully modulate post-junctional α1-adrenergic signaling 
within contracting skeletal muscle in humans, thereby revealing endogenous ACh as a 
mechanism of functional sympatholysis. This is the first study to ascertain a signaling pathway 
that modulates sympathetic vasoconstriction in contracting muscle in humans and, importantly, 
the findings establish a novel, physiological role for ACh in the regulation of muscle blood flow 




CHAPTER 4 – MANUSCRIPT 3 
Endogenous ACh facilitates brachial artery flow-mediated vasodilation in humans 
INTRODUCTION 
The vascular endothelium regulates vessel diameter in response to chemical and 
mechanical cues to ensure tissues receive an adequate supply of blood flow and oxygen. 
Endothelial cells detect changes in intraluminal shear stress, which stimulates endothelium-
dependent vasodilation that is largely attributed to nitric oxide synthesis and initiation of 
endothelium-dependent hyperpolarization (Joannides et al., 1995; Lieberman et al., 1996; 
Bellien et al., 2006). Because flow-induced vasodilation is a critical function of the endothelium, 
flow-mediated dilation (FMD) of the brachial artery is widely evaluated in clinical research as an 
index of vascular health. Endothelial dysfunction precedes and independently predicts 
development of cardiovascular disease (Gokce et al., 2002; Broxterman et al., 2019); thus, FMD 
is often assessed as a primary outcome measure in studies designed to detect or treat vascular 
disease. However, despite the physiological and clinical relevance, the mechanisms by which 
shear stress stimulates nitric oxide production and vasodilation are unclear. 
Flow-mediated dilation corresponds closely with sensitivity to the endothelium-
dependent vasodilator acetylcholine (ACh). Interestingly, activation of muscarinic ACh receptors 
contributes to basal and flow-induced nitric oxide synthesis and vasorelaxation of coronary 
artery rings superfused with effluent from isolated canine conduit arteries (Martin et al., 1996). 
Together with recent evidence that ACh released from endothelial cells mediates calcium 
signaling and nitric oxide production in response to shear in isolated rat carotid arteries (Wilson 
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et al., 2016), these findings suggest that locally-released ACh plays a role in endothelial 
mechanotransduction and flow-mediated dilation. 
Accordingly, the purpose of the present study was to investigate whether endogenous 
ACh facilitates flow-mediated vasodilation in humans. Prior studies indicate that different 
mechanisms underlie conduit artery dilation in response to transient and sustained shear stimuli 
(Mullen et al., 2001; Bellien et al., 2006); therefore, we tested whether intra-arterial infusion of 
atropine to inhibit muscarinic ACh receptors reduces vasodilation of the brachial artery in 
response to a transient or sustained shear stimulus. The results suggest a novel, physiological role 
of ACh in blood flow regulation in humans and provide insight regarding the basic mechanisms 
of flow-mediated vasodilation.  
METHODS 
Participants and ethical approval 
All procedures were approved by the Institutional Review Board at Colorado State 
University and performed according to the standards of the Declaration of Helsinki except for 
registration in a database. After providing written, informed consent, 11 healthy participants 
volunteered for this study (5 women, 6 men; 23 ± 2 y; 26 ± 2% body fat; means ± SE). All 
participants were non-smokers who were free of apparent cardiovascular or metabolic disease.  
Instrumentation and arterial catheterization 
Participants arrived at the laboratory in the morning following an overnight fast and lay 
supine with the experimental arm abducted ~90° and supported slightly above heart level. After 
local anesthesia (2% lidocaine), a physician placed a 20 g, 12 cm catheter in the brachial artery 
using sterile technique. The catheter was inserted at the antecubital fossa and threaded 
proximally such that the tip of the catheter rested midway up the participant’s upper arm (Fig. 
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4.1A). The catheter was connected to a three-way port for intra-arterial drug infusions and a 
continuous drip of heparinized saline. Heart rate was monitored throughout the study with a 
three-lead electrocardiogram (ECG) and arterial blood pressure was monitored with a pressure 
transducer attached to the catheter.   
Brachial artery diameter and blood velocity 
Brachial artery diameter and blood velocity were measured with Doppler ultrasound 
(Vivid7, General Electric, Milwaukee, WI). The catheter was visualized within the artery using a 
12 MHz probe (Fig. 4.1A) and diameter measurements were obtained distal to the tip of the 
catheter (i.e. downstream of intra-arterial drug administration). Images were recorded at end-
diastole for each cardiac cycle using the R wave of the ECG as a trigger for image capture 
(Vascular Imager, Medical Imaging Applications, Coralville, IA) for offline analysis with 
automatic wall tracking software (Brachial Analyzer, Medical Imaging Applications, Coralville, 
IA). During the exercise FMD trial and ACh dose-response, steady-state diameter images were 
recorded in B-mode. During the reactive hyperemia FMD trial, diameter images were recorded 
in duplex mode to allow simultaneous measurement of blood velocity. Velocity was measured 
proximal to the tip of the catheter using a 5 MHz frequency and 60° insonation angle. Mean 
blood velocity (MBV) is reported as the weighted mean of Doppler shift frequencies determined 
via a spectral analyzer (Multigon 500 M, Multigon Industries, Mount Vernon, NY).  
Experimental protocol 
An overview of the experimental timeline is presented in Fig. 4.1B. Following 
catheterization and set-up, graded handgrip exercise and reactive hyperemia were used in 
separate trials to assess FMD, then the vasodilatory response to ACh was determined. All trials 
were completed under control conditions, then atropine was infused and trials were repeated to 
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evaluate the contribution of ACh. Trials were always performed in the same order with 10-15 
min breaks between trials. 
B. Study day timeline
1. Control trials with saline
2. Atropine, trials repeated












Figure 4.1: Experimental protocol.  
The experimental set-up is illustrated in A. Doppler ultrasound was used to measure 
brachial artery diameter and blood velocity. Diameter was measured downstream of the 
arterial catheter to ensure the site of measurement was exposed to atropine. The study day 
timeline is shown in B. Following catheterization and set-up, participants completed a 
graded handgrip exercise protocol to assess flow-mediated dilation (FMD) of the brachial 
artery in response to a sustained shear stimulus. After a ≥20 min break, FMD was assessed 
in response to reactive hyperemia, which produces a robust, transient shear stimulus. This 
trial was followed by a ≥10 min break, then the vasodilatory response to infusion of 
exogenous ACh was evaluated. When control trials were completed, atropine was infused, 
then all trials were repeated in the same order. 
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Rhythmic handgrip exercise 
A graded handgrip exercise protocol was employed to assess FMD of the brachial artery 
in response to a steady-state shear stimulus. Participants performed dynamic handgrip 
contractions to lift a weight 4-5 cm over a pulley system at a rate of 20 contractions per min (1 s 
contraction, 2 s relaxation). The weights corresponded to 10, 15, 20, and 25% of maximal 
voluntary contraction (MVC) force, which was determined prior to the study visit using a 
Stoelting handgrip dynamometer. Two min of baseline data were collected, then participants 
performed handgrip exercise at 10% MVC for 4-5 min to attain steady-state values. To ensure 
clear images without movement artifact, participants briefly stopped contractions at the end of 
each exercise intensity for diameter recordings before beginning the next workload. 
Reactive hyperemia 
A reactive hyperemia protocol was utilized to assess FMD of the brachial artery in 
response to a transient shear stimulus. Following 2 min of baseline recordings, a cuff distal to the 
elbow was inflated to suprasystolic pressure (≥200 mmHg) to occlude forearm blood flow for 5 
min, which results in vasodilation of downstream resistance vessels and produces a reactive 
hyperemic response upon cuff release. Beat-by-beat brachial diameter and blood velocity were 
recorded for 3 min following cuff release to determine FMD and calculate the shear stimulus. 
The ultrasound probe position was maintained with a probe holder to minimize movement and 
the position of the cuff was maintained across control and atropine trials. Data from one 
participant were excluded from analysis for the reactive hyperemia trial because the image 




The vasodilatory response to ACh infusion was evaluated to assess sensitivity to ACh 
and efficacy of the blockade with atropine. Forearm volume (FAV) was determined using dual 
X-ray absorptiometry prior to the study visit for normalization of drug doses. Following 2 min of 
baseline measurements, ACh was infused at 0.5, 1.5, 4.5, and 15 µg/dl FAV/min for 3 min per 
dose with an infusion rate of approximately 2 ml/min. The ACh dose-response trial was not 
performed in one participant due to time restrictions. 
Atropine administration 
Following control trials, atropine was administered through the arterial catheter to inhibit 
muscarinic ACh receptors. A bolus infusion of atropine was administered prior to each trial. 
Initially, a total of 0.2 mg was infused over the course of 3 min as a loading dose, then 
maintenance doses of 0.07 mg were infused over the course of 1 min prior to subsequent trials. 
Due to the length of the exercise trial (~20 min), additional maintenance doses of 0.01 mg were 
infused over 10 s between each exercise intensity.  
Data analysis and calculations 
Data were collected at 250 Hz for later analysis with data processing software (Windaq; 
DATAQ Instruments). Steady-state variables in the exercise trial reflect average values over 30 s 
(MBV, MAP, HR) or 10 cardiac cycles (brachial diameter). The slopes and intercepts for 
diameter vs. shear rate and the change in diameter vs. the change in shear rate from rest were 
calculated for each participant. In the reactive hyperemia trial, variables were assessed for each 
cardiac cycle following cuff release. Diameter measurements were smoothed using a rolling 
average of three cardiac cycle bins and the rolling average was used to identify peak diameter. 
Shear rate was calculated as 8 × MBV ÷ diameter and expressed in s-1. The change in shear rate 
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from either baseline or occlusion was used to calculate shear rate area under the curve (SRAUC), 
which is reported from cuff release to peak diameter and to 2 min post-cuff release. Forearm 
blood flow (FBF) was calculated as π × (diameter ÷ 2)2 × MBV × 60 and expressed in ml/min. 
Forearm vascular conductance (FVC) was calculated as FBF ÷ MAP × 100 and expressed in 
ml/min/100 mmHg. 
 Statistics 
 All data are presented as means ± SE. Steady-state variables in the exercise trial were 
evaluated using two-way (drug × time), repeated-measures ANOVA followed by Tukey’s post-
hoc analysis to compare atropine to control conditions. In the event of non-normal distributions, 
data were log transformed when appropriate. The effect of atropine on relationship between 
diameter and shear rate (slope and intercept) for each participant was evaluated with paired t 
tests. In the reactive hyperemia trial, the effect of atropine on brachial artery diameter at baseline, 
 
Table 4.1: Forearm and systemic hemodynamics during graded handgrip exercise 
 Rest 10% MVC 15% MVC 20% MVC 25% MVC 
Forearm blood flow (ml/min) † 
Control 19 ± 3 92 ± 10 145 ± 14 209 ± 17 277 ± 20 
Atropine 17 ± 2 90 ± 11 149 ± 17 206 ± 21 270 ± 21 
Mean arterial pressure (mmHg) † 
Control 91 ± 2 94 ± 2 96 ± 2 97 ± 2 100 ± 3 
Atropine 92 ± 1 93 ± 1 95 ± 1 97 ± 2 101 ± 3 
Forearm vascular conductance (ml/min) † 
Control 21 ± 4 98 ± 12 151 ± 14 214 ± 16 280 ± 21 
Atropine 18 ± 2 96 ± 11 156 ± 16 211 ± 18 267 ± 18 
Heart rate (beats/min) † 
Control 63 ± 2 65 ± 2 65 ± 2 67 ± 2 69 ± 2 
Atropine 57 ± 2* 62 ± 3 66 ± 3 70 ± 4 73 ± 3 




occlusion, and peak was assessed using two-way (drug × time), repeated-measures ANOVA 
followed by Tukey’s post-hoc comparisons. The effect of atropine on all other variables in the 
reactive hyperemia trial was evaluated with paired t tests.  
RESULTS 
Graded handgrip exercise FMD 
Under control conditions, forearm blood flow increased in parallel with exercise intensity 
(Table 4.1), which resulted in a progressive increase in shear rate at the brachial artery that 






























































































































Figure 4.2: Diameter and shear rate during graded handgrip exercise.  
Atropine did not affect brachial artery diameter at rest but reduced diameter throughout exercise 
(A) and attenuated the change in diameter from rest at higher exercise intensities (B). There was a 
main effect of atropine to increase shear rate (C) and atropine increased the change in shear rate 
from baseline at the higher exercise intensities (D). Values are means ± SE for n = 11 
participants. MVC, maximal voluntary contraction. *P < 0.05 vs. control 
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evoked flow-mediated dilation (Figs 4.2 & 4.3). Inhibition of muscarinic ACh receptors with 
atropine had no effect on brachial diameter or forearm hemodynamics at rest; however, resting 
heart rate was slightly lower in the atropine trial (Fig. 4.2 & Table 4.1). Although atropine did 
not impact forearm blood flow during exercise, it attenuated vasodilation of the brachial artery 
such that diameter was reduced compared to control exercise (Table 4.1 & Fig. 4.2). There was a 
main effect of atropine to increase shear rate and the exercise-induced increase in shear rate was 
greater during the 15, 20, and 25% MVC workloads compared to control (Fig. 4.2). Thus, 
brachial artery diameter and vasodilation was reduced for a given shear stimulus when ACh  
receptors were inhibited by atropine (Fig. 4.3 & Table 4.2). Atropine reduced the slope of the  
relationship between vasodilation and the shear stimulus by 38 ± 8% (Fig. 4.3 & Table 4.2). 
 

























Figure 4.3: Flow-mediated dilation during graded 
handgrip exercise.  
The percent change in brachial artery diameter from 
rest is plotted against the change in shear rate for each 
exercise intensity. Dotted lines illustrate the average 
relationship between the change in diameter and 
change in shear for n = 11 participants; the slope and 
intercept are reported in Table 4.2. Atropine reduced 
the slope describing the relationship between brachial 
artery vasodilation and the change in shear rate by 38 
± 8%. * P < 0.05 control vs. atropine slope 
58 
 
Table 4.2: Slopes and intercepts during exercise 
 Control Atropine 
Diameter vs. Shear Rate 
Slope (mm/s × 10-4) 6.3 ± 1.0 3.4 ± 0.4* 
Intercept (mm) 3.2 ± 0.1 3.2 ± 0.2  
Δ Diameter vs. Δ Shear Rate 
Slope (mm/s × 10-2) 8.0 ± 1.4 4.1 ± 0.5* 
Intercept (mm) -0.2 ± 0.1 -0.1 ± 0.0 
Δ Diameter (%) vs. Δ Shear Rate 
Slope (% Δ/s × 10-2) 2.4 ± 0.4 1.3 ± 0.1* 
Intercept (% Δ) -4.8 ± 1.6 -3.0 ± 1.3 
Values are means ± SE for n = 11 participants.  
* P < 0.05 vs. control 
 
Reactive hyperemia FMD 
In the control trial, 5 min of occlusion to produce reactive hyperemia evoked a rapid 
increase in shear rate at the brachial artery which was followed by brachial vasodilation that 
peaked by 36 ± 5 s after cuff release (Figs 4.4 & 4.5 and Table 4.3). Atropine did not affect 
baseline diameter; however, constriction of the brachial artery was observed during cuff 
occlusion in the atropine trial which was not observed during control conditions (Table 4.3 and 
Fig. 4.4A). Therefore, in addition to traditional analysis of flow-mediated dilation from baseline 
diameter, we also assessed vasodilation from the occlusion time point. Atropine reduced peak 
diameter and slowed the time course of vasodilation such that peak diameter did not occur until 
63 ± 11 s after cuff release (Table 4.3). When dilation and the shear stimulus were calculated 
from baseline, atropine attenuated flow-mediated dilation despite an augmented shear rate such 
that the percent change in brachial artery diameter was reduced by 35 ± 16% when normalized to 
SRAUC (Fig. 4.5 panels A, C, & E). When calculated from occlusion, atropine did not affect the 
percent change in brachial diameter (Fig. 4.5B). However, atropine resulted in a higher shear 
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stimulus (Fig. 4.5D) such that vasodilation from occlusion still tended to be reduced when 
normalized to SRAUC (Fig. 4.5F; P = 0.07 vs. control). Similar results were observed when 
comparing the absolute change in diameter rather than the percent change (data not shown).  
Table 4.3: Reactive hyperemia FMD trial 
 Control Atropine 
Brachial artery diameter (mm) 
Baseline 3.26 ± 0.17 3.26 ± 0.19 
Occlusion 3.26 ± 0.18 3.19 ± 0.18* 
Peak 3.48 ± 0.20 3.42 ± 0.22* 
Low flow-mediated constriction (%) 
 -0.1 ± 0.7 -2.1 ± 0.8* 
Time to peak diameter (s) 
 36 ± 5 63 ± 11* 
Shear rate AUC to 2 min (arbitrary units) 
From BL 25,407 ± 3,734 33,477 ± 3,354* 
From occl. 29,870 ± 4,472 39,215 ± 3,785* 
Values are means ± SE for n = 10 participants. 
AUC, area under the curve; BL, baseline; FMD, 























































































Figure 4.4: Time course of flow-mediated dilation in 
response to reactive hyperemia.  
The time course of the change in brachial artery 
diameter from baseline (A), shear rate (B), and 
diameter normalized to shear rate (C) is shown for 









































































































































































































Figure 4.5: Flow-mediated dilation in response to reactive hyperemia.  
Traditional analysis of flow-mediated dilation from baseline is shown in panels A, C, & E. 
Atropine reduced peak vasodilation of the brachial artery following cuff release (A) and 
increased the shear stimulus (C) such that the percent change in brachial diameter was 
diminished by 35 ± 16% when normalized to SRAUC (E). An additional analysis of flow-
mediated dilation from occlusion is shown in panels B, D, & F. Atropine did not affect the 
peak change in brachial artery diameter from occlusion (B); however, it increased the shear 
stimulus (D) such that vasodilation from occlusion tended to be reduced when normalized to 
SRAUC (F). Values are means ± SE for n = 10 participants. AUC, area under the curve; SR, 




Under control conditions, infusion of ACh caused substantial vasodilation when assessed 
as the percent change in forearm vascular conductance or brachial artery diameter (Fig. 4.6). 
Although the lowest dose of ACh (0.5 µg/dl FAV/min) caused only a mild increase in forearm 
blood flow (~50 ml/min), it resulted in marked vasodilation of the brachial artery that surpassed 
that observed during the highest exercise intensity (Fig. 4.6B vs. Fig. 4.3). Atropine reduced total 
vasodilation (Δ FVC %) during ACh infusion by 83 ± 3% (averaged across all doses) and 
reduced brachial artery vasodilation by 74 ± 7% (averaged across all doses).  
DISCUSSION 
The present study was designed to determine whether endogenous ACh facilitates flow-
mediated vasodilation of conduit arteries in humans. We utilized intra-arterial infusion of 
atropine to inhibit muscarinic receptors at the brachial artery and assessed flow-mediated 
vasodilation in response to both steady-state and transient shear stimuli. The key findings are as 
follows: 1) Atropine reduced brachial artery vasodilation in response to graded, steady-state 
elevations in shear rate produced by handgrip exercise by 38 ± 8%. 2) Atropine also reduced 
brachial artery vasodilation in response to a robust, transient increase in shear rate produced by 
the reactive hyperemic response to 5 min of forearm occlusion by 35 ± 16%. These results 
demonstrate that endogenous ACh elicits conduit artery vasodilation in response to increased 
flow and reveal a novel, physiological role of ACh in peripheral blood flow regulation in 
humans. 
Flow-mediated dilation is a fundamental homeostatic function by which arteries 
accommodate changes in blood flow. Because it is mediated by the endothelium, FMD of  
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conduit arteries is commonly assessed in clinical research as an index of endothelial function. 
This test has considerable prognostic value: impaired FMD of the brachial or radial artery in 
response to reactive hyperemia precedes development of cardiovascular disease and is an 
independent predictor of future cardiovascular events (Celermajer et al., 1992; Gokce et al., 

















































































Figure 4.6: Vasodilatory response to acetylcholine infusion.  
The percent change in forearm vascular conductance (A) 
and brachial artery diameter (B) in response to graded 
infusions of exogenous ACh are shown for n = 10 
participants. Atropine diminished total vasodilation (A) 
by 83 ± 3% and reduced brachial artery vasodilation (B) 
by 74 ± 7%. ACh, acetylcholine; FAV, forearm volume. 
* P < 0.05 vs. control 
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considerable interest in identifying the mechanisms that underlie flow-mediated dilation. Prior 
studies suggest that distinctive pathways contribute to vasodilation in response to sustained and 
transient increases in shear stress (Mullen et al., 2001) and these responses are differentially 
affected in clinical populations (Mullen et al., 2001; Bellien et al., 2006; Findlay et al., 2013; 
Lorthioir et al., 2015). Thus, determining the mechanisms that underlie FMD in response to 
sustained and transient shear stimuli may provide distinctive insight to vascular function. 
FMD in response to sustained shear during handgrip exercise 
In the present study, local inhibition of muscarinic ACh receptors did not alter basal 
brachial artery diameter distal to the site of atropine infusion; however, it reduced brachial artery 
vasodilation in response to graded bouts of handgrip exercise. Despite the smaller diameter, 
exercise hyperemia was preserved by a reciprocal increase in blood velocity; therefore, atropine 
augmented the shear stimulus at a given exercise intensity. In combination, these results indicate 
that atropine reduces the slope of the relationship between brachial artery diameter and shear rate 
such that less vasodilation is observed for a given shear stimulus. Thus, endogenous ACh is in 
part responsible for conduit artery vasodilation in response to a sustained increase in shear stress. 
Although atropine diminished flow-mediated dilation during exercise, it had no impact on 
forearm blood flow. This is in agreement with prior studies which have shown no effect of 
atropine on exercise hyperemia (Buckwalter et al., 1997; Shoemaker et al., 1997). Given the 
physiological and clinical importance of flow-mediated dilation, it is noteworthy that preventing 
a large portion of conduit artery dilation does not alter muscle blood flow. Casey & Joyner 
(Casey & Joyner, 2009) examined the impact of brachial artery obstruction on exercise 
hyperemia and observed that inflation of a balloon within the artery caused only a temporary 
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reduction in forearm blood flow – compensatory vasodilation of the downstream resistance 
vasculature largely restored perfusion.  
FMD in response to reactive hyperemia following cuff occlusion 
As in the exercise trial, atropine had no effect on baseline diameter but attenuated 
brachial artery vasodilation in response to reactive hyperemia. The reduction in FMD occurred 
despite a greater shear stimulus compared to control conditions. Interestingly, the effect of 
atropine was partly due to vasoconstriction of the brachial artery that occurred when brachial 
blood flow was reduced by cuff occlusion, indicating an additional role of ACh in mitigating 
low-flow mediated constriction (L-FMC). Compared to flow-mediated dilation, much less is 
known about vasoconstriction of conduit arteries during periods of low shear stress. L-FMC of 
the radial artery has been proposed to be a marker of vascular function that may provide insight 
regarding basal flow-induced vasodilation (Gori et al., 2008; Dawson et al., 2012). In contrast to 
the radial artery, the prevalence and magnitude of L-FMC is reduced in the brachial artery.  
Our results are in line with studies that have shown that constriction of the brachial artery 
during the occlusion period corresponds with a blunted and delayed vasodilatory response 
(Harrison et al., 2011; Irace et al., 2016; Harbin et al., 2018). As both a reduced magnitude of 
FMD and a latent response are associated with cardiovascular risk (Irace et al., 2014), 
constriction of the brachial artery during occlusion may actually be reflective of endothelial 
dysfunction. In support of this, L-FMC of the brachial artery is augmented in patients with 
unstable atherosclerosis and lessened in parallel with improvements in FMD in patients 
recovering from myocardial infarction (Spiro et al., 2011). Collectively, these studies suggest 
that the degree of constriction during occlusion is an essential contributing factor that reduces 
FMD following reactive hyperemia. The results of the present study demonstrate that ACh 
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normally counteracts L-FMC in healthy individuals. To our knowledge, this is the first study to 
identify a mechanism that regulates L-FMC in the brachial artery. 
Atropine did not affect baseline diameter, whereas it enhanced L-FMC and blunted FMD. 
These observations are somewhat surprising given evidence that ACh is released from 
endothelial cells in response to shear stress. Many Gq-coupled protein receptors, including M5 
muscarinic receptors, exhibit mechanosensitivity such that deformation of the cell membrane 
enhances sensitivity to ligand binding (Mederos y Schnitzler et al., 2008), which may explain the 
lack of effect of atropine on baseline diameter compared to when shear rate is elevated. 
However, because shear rate was higher at baseline compared to during occlusion, a greater role 
of ACh would be expected on baseline diameter whereas we only observed an effect during 
occlusion. The reasons for this discrepancy are not clear. It is possible that ACh is not normally 
involved in maintaining baseline diameter or that other mechanisms are able to compensate for 
the loss of ACh under resting conditions. During occlusion, a reduction in shear and thus 
diminished basal flow-mediated dilation could unmask sympathetic and myogenic 
vasoconstrictor tone. We have observed that ACh alters post-junctional sensitivity to 
α-adrenergic receptor activation; therefore, it is possible that ACh is obligatory for preventing 
sympathetic vasoconstriction during a low-flow condition. Interestingly, intra-arterial atropine in 
combination with sympathetic α and β receptor blockade by phentolamine and propranolol did 
not affect radial artery FMD in response to sustained hand warming (Mullen et al., 2001), which 
raises the possibility that the effect of atropine in the present study may involve an interaction 
with sympathetic signaling. However, the dose of atropine administered by Mullen et al. was 
approximately 200 times lower than the dose administered in the present study and they did not 
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report the blockade efficacy; thus, the lack of effect of atropine on radial artery dilation due to 
hand warming may be due to insufficient inhibition of muscarinic receptors. 
Mechanisms of flow-mediated vasodilation 
Prior investigations have explored several potential pathways as mechanisms of flow-
mediated dilation. Initial studies showed that inhibition of nitric oxide synthesis abolished FMD 
in response to reactive hyperemia (Lieberman et al., 1996; Mullen et al., 2001); indeed, 
vasodilation was converted to constriction in some studies (Joannides et al., 1995; Doshi et al., 
2001). These findings led to the prevalent view that FMD serves as an index of nitric oxide 
bioavailability. Subsequent studies have indicated a lesser role for nitric oxide or observed 
preserved FMD during inhibition of nitric oxide synthesis (Pyke et al., 2010; Parker et al., 2011; 
Wray et al., 2013), which suggests that nitric oxide is not always obligatory for FMD in response 
to reactive hyperemia. Along these lines, the reliance on nitric oxide varies among different 
protocols employed to induce FMD. Nitric oxide dependence is reduced when longer durations 
of cuff occlusion are utilized to provoke reactive hyperemia (Mullen et al., 2001) or when the 
cuff is placed proximal to the site of measurement (Doshi et al., 2001). Compared to the transient 
shear stimulus associated with reactive hyperemia protocols, a lesser contribution of nitric oxide 
is observed during sustained increases in shear rate as a result of hand warming or distal 
vasodilator infusion (Mullen et al., 2001; Bellien et al., 2006), whereas the vasodilatory response 
to graded handgrip exercise is largely nitric oxide dependent (Wray et al., 2011). 
Endothelium-derived hyperpolarization has also been investigated as a mechanism of 
conduit artery FMD. An increase in cytosolic Ca2+ within endothelial cells causes 
hyperpolarization via K+ efflux through Ca2+-activated K+ (KCa) channels and enhances synthesis 
of diffusible hyperpolarizing factors such as epoxyeicosatrienoic acids (EETs). 
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Hyperpolarization of endothelial cells spreads through gap junctions to underlying vascular 
smooth muscle cells and EETs diffuse to the vascular smooth muscle where they initiate 
hyperpolarization via KCa channels. Ultimately, hyperpolarization causes relaxation of vascular 
smooth muscle and thus vasodilation. Inhibition of KCa channels reduces FMD in response to 
hand warming, and this effect is magnified when combined with inhibition of nitric oxide 
synthesis (Bellien et al., 2006). Similarly, inhibition of a cytochrome P450 epoxygenase to 
reduce synthesis of EETs attenuates FMD in response to both hand warming and reactive 
hyperemia, and this effect is also enhanced during combined blockade of nitric oxide production 
(Bellien et al., 2006; Fischer et al., 2007). These findings support an important contribution of 
endothelium-derived hyperpolarization to flow-mediated dilation and suggest an interaction 
between hyperpolarization and nitric oxide signaling.  
Taken together, previous studies indicate that nitric oxide and endothelium-derived 
hyperpolarization contribute to flow-mediated dilation of conduit arteries in humans, although 
differences in the shear stimulus and crosstalk between pathways obscure definitive conclusions 
regarding the relative importance of each mechanism. A key aspect of the present study is that 
ACh is capable of stimulating both nitric oxide synthesis and endothelium-derived 
hyperpolarization; thus, ACh may serve as an upstream mechanism by which shear stress is 
transduced to vasodilation through recruitment of these pathways. The idea that ACh is a 
common precursor to nitric oxide synthesis and hyperpolarization in response to increased flow 
could also explain the heterogeneous mediators of flow-induced vasodilation, as a reduction in 
one pathway could shift the response toward reliance on the other pathway. We observed a 
similar atropine-sensitive component of FMD in response to both sustained and transient shear 
stimuli, whereas prior studies have identified differential contributions of nitric oxide and 
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hyperpolarizing pathways depending on the nature of the shear stimulus. This raises the 
possibility that the contribution of ACh is comparable between trials, yet the effects are shifted 
toward different downstream mediators with prolonged exposure. 
Although atropine substantially blunted FMD, residual vasodilation of the brachial artery 
was still observed in response to both handgrip exercise and reactive hyperemia. There is 
considerable redundancy in the signaling mechanisms that regulate blood flow such that 
upregulation of one pathway compensates for loss of another; therefore, we speculate that 
additional mechanisms are responsible for the remaining vasodilation. However, it is also 
possible that incomplete inhibition of ACh receptors with atropine could explain a portion of the 
residual FMD responses observed.  
Muscarinic receptor distribution 
Muscarinic receptors are present on both endothelial and vascular smooth muscle cells, 
and all muscarinic receptor subtypes have been identified in the mammalian vasculature. In small 
arteries isolated from mouse skeletal muscle, mRNA expression of the M3 subtype is markedly 
greater than other subtypes and knockout of the M3 receptor abolishes vasodilation to ACh, 
whereas knockout of M1 or M5 subtypes has no effect (Gericke et al., 2011). The M3 subtype is 
also responsible for femoral artery relaxation to ACh in mice, where the effects are mediated 
entirely by nitric oxide synthesis (Bény et al., 2008). Although atropine is a nonselective blocker 
of muscarinic receptors, studies in the human forearm circulation also support a predominant role 
of the M3 receptor in the vasodilatory response to ACh (Bruning et al., 1994; Attinà et al., 2008).  
In contrast to muscarinic receptors on endothelial cells, activation of M3 receptors on 
vascular smooth muscle cells results in contraction. Removal of the endothelium or endothelial 
dysfunction unmasks a vasoconstrictor response to ACh (Furchgott & Zawadski, 1980; Lüscher 
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& Vanhoutte, 1986; Treasure et al., 1992). Interestingly, the vasodilatory response to flow has 
also been reported to revert to vasoconstriction when nitric oxide synthesis is pharmacologically 
inhibited (Joannides et al., 1995) and in clinical populations at high risk for cardiovascular 
events (Nguyen et al., 2014); thus, it is possible that ACh release in response to shear activates 
muscarinic receptors on both endothelial and vascular smooth muscle cells and that the net 
vasodilatory response shifts to constriction in disease states.  
It is likely that the contribution of ACh to flow-induced vasodilation varies among 
vascular beds and at different levels of the vascular tree. The downstream signaling pathways 
involved in the response to ACh differ depending on the properties of the vascular bed and size 
of the artery. For instance, vasodilation of large conduit arteries in response to ACh is primarily 
attributed to nitric oxide, whereas dilation of arterioles in response to ACh involves substantial 
activation of hyperpolarizing pathways. In addition to differences in the cellular response to 
ACh, muscarinic receptor expression and ACh release and degradation may differ throughout the 
vasculature. Thus, the extent to which ACh contributes to flow-mediated dilation in other arteries 
is unclear.  
Limitations 
Several limitations of the present study warrant discussion. First, we did not measure 
circulating ACh and cannot confirm that it increases with elevated shear rate. Although ACh has 
been detected in plasma with the use of acetylcholinesterase inhibitors (Kawashima et al., 1987), 
ACh is rapidly degraded in circulation and thus challenging to measure. Of note, many 
Gq-coupled receptors exhibit mechanosensitivity and can initiate ligand-independent responses 
(Mederos y Schnitzler et al., 2008); therefore, it is possible that muscarinic receptors per se 
mediate the response in the absence of ACh. However, treatment with acetylcholinesterase 
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inhibitors to limit ACh degradation enhances flow-induced endothelial Ca2+ signaling and 
vasorelaxation in ex vivo preparations (Martin et al., 1996; Wilson et al., 2016), which suggests 
that ACh is released in response to shear. 
Another limitation of the current study is that the drug and trial order was maintained 
across all participants; therefore, we cannot exclude a general effect of time and repeated 
exposure to shear stimuli on the responses observed. Because the long half-life of atropine 
precludes randomization of drug order, control trials were always completed first. In a separate 
study in our laboratory, brachial artery FMD was preserved during repeated, steady-state bouts 
of handgrip exercise (slope of percent change in diameter per change in shear: 2.4 ± 0.5 vs. 2.3 ± 
0.4 %/s × 10-2, P = 0.44). Thus, the effect of atropine to reduce the slope from 2.4 ± 0.4 to 1.3 ± 
0.1 %/s × 10-2 in the present study is unlikely to be due to repeated bouts of exercise. Although 
we have not assessed the effects of repeated measurements on FMD in response to reactive 
hyperemia in our laboratory, Pyke and colleagues (Pyke et al., 2010; Pyke & Jazuli, 2011) have 
demonstrated that exposure to several bouts of reactive hyperemia or handgrip exercise does not 
impact flow-mediated vasodilation. It is also possible that the exercise trial affected the reactive 
hyperemia trial in the present study, as the order of these trials was held constant for all 
participants. Llewellyn et al. (Llewellyn et al., 2012) reported a reduction in reactive hyperemia 
FMD immediately following treadmill running; however, normalization to shear rate abolished 
the effect of exercise. To mitigate potential carryover effects, we included a 20 min break 
between exercise and reactive hyperemia trials. Ultimately, any potential impact of exercise on 




We measured brachial artery diameter downstream of the arterial catheter to ensure the 
site of measurement was exposed to atropine. However, because the catheter interfered with the 
Doppler signal, we were unable to measure blood velocity within the same segment of the vessel 
as diameter measurements were obtained. Therefore, velocity was assessed proximal to the tip of 
the catheter with the Doppler gate placed as close as possible while avoiding interference. If 
atropine did not inhibit muscarinic receptors at this location, it is possible that flow-mediated 
dilation remained intact. If this were the case, it is likely that our measurements of velocity and 
therefore shear rate underestimate the actual shear stimulus at the site of diameter measurement 
during the atropine condition.  
Perspectives 
Vascular sensitivity to ACh is reduced in aging and clinical populations, and a reduced 
vasodilatory response to ACh is an independent predictor of cardiovascular disease risk. Due to 
its close association with sensitivity to ACh, FMD of the brachial artery is commonly used as a 
surrogate measure of endothelial function. The results of this study clarify the correlation 
between the vasodilatory response to ACh and flow-mediated dilation through evidence that 
ACh itself partially mediates FMD. Understanding the signaling pathways that underlie flow-
mediated dilation lays the foundation for future approaches to improve endothelial health, which 
has broad implications for preventing and treating cardiovascular disease. 
CONCLUSIONS 
The present study provides evidence that endogenous ACh facilitates flow-mediated 
vasodilation of the brachial artery in humans. The contribution of ACh to flow-mediated dilation 
is comparable during sustained and transient increases in shear rate induced by handgrip exercise 
and reactive hyperemia, respectively. These results demonstrate that ACh regulates conduit 
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artery diameter in response to changes in shear rate and reveal a novel, physiological role of ACh 





CHAPTER 5 – PERSPECTIVES & CONCLUSIONS 
This collection of studies provides meaningful insight into the basic physiology 
underlying blood flow regulation in humans and reveal a novel, physiological role of endogenous 
ACh as a regulator of peripheral vascular tone. In Experiment 1, we show that ACh interacts 
with ATP such that combined activation of the endothelium with both agonists amplifies 
vasodilation, which suggests that activation of the endothelium enhances its sensitivity to other 
stimuli. In addition to augmenting vasodilation, we show that endothelium-dependent agonists 
interact to modulate sensitivity to sympathetic vasoconstriction. These observations highlight the 
endothelium as a key site for integrating multiple vasoactive inputs to efficiently regulate tissue 
blood flow. In Experiment 2, we demonstrate that endogenous ACh overrides sympathetic 
vasoconstriction within contracting skeletal muscle. To the best of our knowledge, this is the first 
study to elucidate an essential mechanism of functional sympatholysis, which is critical to ensure 
adequate delivery of oxygen and nutrients to metabolically active tissue. Finally, in Experiment 
3, we establish that endogenous ACh mediates a substantial portion of brachial artery 
vasodilation in response to shear stimuli. We also observe that ACh counteracts vasoconstriction 
of the brachial artery during periods of low blood flow; thus, we conclude that ACh regulates 
conduit artery diameter in response to changes in shear rate when blood flow is elevated or 
reduced. Taken together, these findings indicate that endogenous ACh plays a key role in 
regulating peripheral vascular tone at the level of the resistance vasculature and conduit arteries 
in humans. 
Vascular sensitivity to ACh (i.e. endothelial function) is reduced with age and in clinical 
populations, and reduced sensitivity to ACh is an independent risk factor that often precedes 
development of cardiovascular disease. Aging and many disease states are also characterized by 
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elevated sympathetic nervous system activity, and the ability of contracting skeletal muscle to 
override sympathetic vasoconstriction is impaired in older adults and clinical populations. The 
combination of endothelial dysfunction, elevated sympathetic outflow, and an inability to blunt 
sympathetic vasoconstriction during exercise results in malperfusion of active skeletal muscle. 
This impairment in blood flow and oxygen delivery leads to accumulation of metabolites, which 
further increases sympathetic activity, elevates blood pressure, and accelerates development of 
fatigue. Taken together, our findings implicate endogenous ACh in vasodilation within the 
skeletal muscle resistance vasculature as well as conduit arteries and demonstrate that ACh 
modulates sympathetic signaling within contracting muscle. These conclusions have 
considerable implications for understanding exercise intolerance in clinical populations and lay 
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